Belgian Cancer Registry

CANCER FACT SHEET 2024
LUNG CANCER
ICD-10 C34

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. For lung cancer, stage IV means the cancer has spread to other organs. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

SCLC: Small cell lung cancer.

NSCLC: Non-small cell lung cancer.

- **SCC:** Squamous cell carcinoma, a type of non-small cell lung cancer.
- **ADC:** Adenocarcinoma, a type of non-small cell lung cancer.

– **LCC:** Large cell undifferentiated carcinoma, a type of non-small cell lung cancer.

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Lung cancer incidence: by region 5

1.1.1. Lung cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Lung cancer incidence: by tumour stage 7

1.2.1. Lung cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.2. Lung cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.2.3. Lung cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.2.4. Lung cancer incidence by histological type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 9

2. CANCER INCIDENCE TRENDS 11

2.1. Lung cancer incidence trends: by region 11

2.1.1. Lung cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 11

2.1.2. Lung cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 13

2.2. Lung cancer incidence trends: by tumour stage 14

2.2.1. Lung cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 14

2.3. Lung cancer incidence trends: by age group 16

2.3.1. Lung cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 16

2.3.2. Lung cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 17

2.4. Lung cancer incidence trends: by histological type 18

2.4.1. Lung cancer incidence trends in males, by histological type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 18

2.4.2. Lung cancer incidence trends in females, by histological type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 20

3. CANCER PREVALENCE 22

3.1. Lung cancer prevalence: by region 22

3.1.1. Lung cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 22

4. CANCER SURVIVAL 23

4.1. Lung cancer survival: by region 23

4.1.1. Lung cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024 23

4.2. Lung cancer survival: by histological type and tumour stage 25

4.2.1. Lung cancer survival by histological type, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024 25
4.2.2. Lung cancer survival by histological type, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2015-2024 30
4.2.3. Lung cancer survival by histological type, stage and sex: number at risk and net survival probabilities, 2015-2024 35
5. CANCER SURVIVAL TRENDS 40
5.1. Lung cancer survival trends: by tumour stage 40
5.1.1. Lung cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024 40
6. CANCER MORTALITY 42
6.1. Lung cancer mortality: by region 42
6.1.1. Lung cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 42
7. CANCER MORTALITY TRENDS 44
7.1. Lung cancer mortality trends: by region 44
7.1.1. Lung cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 44
7.1.2. Lung cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 46

1.1. Lung cancer incidence: by region

1.1.1. Lung cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	1	0	3	2	6	10	36	93	189	414	688	1,028	1,146	1,142	616	325	78	2	5,779	104.0
	[0.0]	[0.0]	[0.3]	[0.0]	[0.9]	[0.5]	[1.5]	[2.6]	[9.3]	[24.9]	[48.1]	[103.9]	[181.1]	[316.4]	[426.7]	[536.2]	[486.8]	[395.7]	[239.3]	[31.4]	[99.7]	(101.3; 106.7)
Brussels	0	0	1	0	0	0	3	0	3	16	21	37	54	55	63	59	26	15	5	0	358	89.6
	[0.0]	[0.0]	[2.5]	[0.0]	[0.0]	[0.0]	[5.6]	[0.0]	[6.6]	[36.3]	[50.9]	[102.1]	[182.8]	[252.9]	[370.9]	[458.4]	[316.0]	[296.2]	[222.7]	[0.0]	[58.5]	(80.1; 99.1)
Flanders	0	0	0	0	2	2	3	8	20	37	82	183	349	566	664	696	430	225	52	1	3,320	95.8
	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[1.0]	[1.4]	[3.7]	[9.0]	[17.4]	[36.3]	[76.6]	[150.2]	[281.9]	[399.8]	[515.3]	[513.3]	[404.6]	[237.7]	[23.8]	[98.3]	(92.5; 99.1)
Wallonia	0	0	0	0	1	0	0	2	13	40	86	194	285	407	419	387	160	85	21	1	2,101	122.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[1.7]	[11.1]	[34.3]	[68.4]	[157.1]	[241.4]	[397.7]	[489.9]	[595.1]	[463.0]	[396.1]	[247.6]	[62.3]	[116.2]	(117.3; 127.9)
Females																						
Belgium	1	0	0	0	1	3	4	13	43	72	128	282	600	761	816	648	351	131	43	5	3,902	61.8
	[0.3]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[1.0]	[3.4]	[11.1]	[19.5]	[33.2]	[71.8]	[155.5]	[220.6]	[273.3]	[253.1]	[201.8]	[96.7]	[59.7]	[23.1]	[65.4]	(59.8; 63.7)
Brussels	0	0	0	0	0	0	0	0	4	9	10	23	29	46	53	43	31	15	2	2	267	54.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[8.8]	[21.5]	[25.9]	[66.9]	[94.9]	[182.9]	[246.2]	[232.0]	[242.1]	[155.5]	[35.4]	[95.3]	[41.9]	(47.9; 61.1)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	1	0	0	0	0	0	1	10	23	37	59	141	325	425	447	391	208	79	23	1	2,171	57.1
	[0.6]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[4.6]	[10.3]	[17.5]	[26.6]	[60.5]	[140.2]	[205.7]	[252.3]	[252.7]	[189.8]	[91.1]	[50.8]	[7.8]	[63.0]	(54.7; 59.5)
Wallonia	0	0	0	0	1	3	3	3	16	26	59	118	246	290	316	214	112	37	18	2	1,464	72.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.8]	[2.5]	[2.5]	[13.5]	[22.2]	[47.0]	[94.3]	[198.9]	[256.3]	[316.4]	[258.6]	[217.6]	[94.5]	[85.3]	[30.1]	[77.7]	(68.6; 76.0)

1.2. Lung cancer incidence: by tumour stage

1.2.1. Lung cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	162 [4.8]	749 [76.9]	605 [131.3]	1,516 [26.2]	27.4 (26.0; 28.7)	149 [4.5]	716 [69.6]	375 [56.9]	1,240 [20.8]	19.7 (18.6; 20.8)
II	46 [1.4]	213 [21.9]	163 [35.4]	422 [7.3]	7.6 (6.9; 8.4)	31 [0.9]	148 [14.4]	85 [12.9]	264 [4.4]	4.2 (3.7; 4.7)
III	122 [3.6]	497 [51.1]	354 [76.9]	973 [16.8]	17.5 (16.4; 18.6)	86 [2.6]	351 [34.1]	170 [25.8]	607 [10.2]	9.6 (8.8; 10.4)
IV	404 [11.9]	1,331 [136.7]	985 [213.8]	2,720 [46.9]	48.9 (47.0; 50.7)	260 [7.8]	920 [89.4]	517 [78.4]	1,697 [28.4]	26.9 (25.6; 28.2)
X/NA	19 [0.6]	72 [7.4]	56 [12.2]	148 [2.6]	2.7 (2.2; 3.1)	20 [0.6]	42 [4.1]	31 [4.7]	94 [1.6]	1.5 (1.2; 1.8)

1.2.2. Lung cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	121 [3.6]	443 [45.5]	188 [40.8]	753 [13.0]	13.3 (12.3; 14.3)	119 [3.6]	456 [44.3]	121 [18.4]	696 [11.7]	11.3 (10.4; 12.1)
II	33 [1.0]	146 [15.0]	48 [10.4]	227 [3.9]	4.0 (3.5; 4.5)	25 [0.7]	86 [8.4]	31 [4.7]	142 [2.4]	2.3 (1.9; 2.7)
III	23 [0.7]	72 [7.4]	32 [6.9]	127 [2.2]	2.3 (1.9; 2.7)	22 [0.7]	60 [5.8]	25 [3.8]	107 [1.8]	1.7 (1.4; 2.1)
IV	61 [1.8]	233 [23.9]	132 [28.7]	426 [7.3]	7.6 (6.9; 8.3)	51 [1.5]	166 [16.1]	68 [10.3]	285 [4.8]	4.6 (4.0; 5.1)
X/NA	515 [15.2]	1,968 [202.2]	1,763 [382.7]	4,246 [73.2]	76.9 (74.5; 79.2)	329 [9.8]	1,409 [136.9]	933 [141.6]	2,672 [44.8]	42.0 (40.4; 43.5)

1.2.3. Lung cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	158 [4.7]	715 [73.5]	596 [129.4]	1,470 [25.4]	26.6 (25.2; 27.9)	144 [4.3]	707 [68.7]	366 [55.5]	1,217 [20.4]	19.3 (18.2; 20.4)
II	50 [1.5]	238 [24.4]	161 [35.0]	449 [7.7]	8.1 (7.3; 8.8)	35 [1.0]	153 [14.9]	84 [12.7]	272 [4.6]	4.3 (3.8; 4.8)
III	126 [3.7]	508 [52.2]	364 [79.0]	998 [17.2]	18.0 (16.8; 19.1)	94 [2.8]	365 [35.5]	183 [27.8]	642 [10.8]	10.2 (9.4; 11.0)
IV	405 [12.0]	1,348 [138.5]	993 [215.6]	2,746 [47.4]	49.3 (47.5; 51.2)	261 [7.8]	926 [90.0]	518 [78.6]	1,705 [28.6]	27.0 (25.7; 28.3)
X/NA	14 [0.4]	53 [5.4]	49 [10.6]	116 [2.0]	2.1 (1.7; 2.5)	12 [0.4]	26 [2.5]	27 [4.1]	66 [1.1]	1.0 (0.8; 1.3)

1.2.4. Lung cancer incidence by histological type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Histological types	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
SCLC	**I**	4 [0.1]	14 [1.4]	8 [1.7]	26 [0.4]	0.5 (0.3; 0.7)	2 [0.1]	17 [1.7]	0 [0.0]	19 [0.3]	0.3 (0.2; 0.4)
	II	3 [0.1]	13 [1.3]	6 [1.3]	22 [0.4]	0.4 (0.2; 0.6)	0 [0.0]	13 [1.3]	8 [1.2]	21 [0.4]	0.3 (0.2; 0.5)
	III	16 [0.5]	69 [7.1]	38 [8.2]	123 [2.1]	2.2 (1.8; 2.6)	26 [0.8]	83 [8.1]	32 [4.9]	141 [2.4]	2.3 (1.9; 2.6)
	IV	68 [2.0]	284 [29.2]	159 [34.5]	511 [8.8]	9.1 (8.3; 9.9)	41 [1.2]	209 [20.3]	108 [16.4]	358 [6.0]	5.7 (5.1; 6.3)
	X/NA	3 [0.1]	7 [0.7]	7 [1.5]	17 [0.3]	0.3 (0.2; 0.5)	2 [0.1]	2 [0.2]	1 [0.2]	5 [0.1]	0.1 (0.0; 0.2)
NSCLC	**I**	119 [3.5]	549 [56.4]	348 [75.5]	1,016 [17.5]	18.2 (17.1; 19.3)	105 [3.1]	513 [49.8]	207 [31.4]	825 [13.8]	13.2 (12.3; 14.1)
	II	37 [1.1]	202 [20.8]	126 [27.4]	365 [6.3]	6.5 (5.9; 7.2)	29 [0.9]	131 [12.7]	56 [8.5]	216 [3.6]	3.4 (3.0; 3.9)
	III	109 [3.2]	414 [42.5]	288 [62.5]	811 [14.0]	14.5 (13.5; 15.6)	65 [1.9]	269 [26.1]	125 [19.0]	459 [7.7]	7.3 (6.6; 8.0)
	IV	320 [9.5]	1,016 [104.4]	713 [154.8]	2,049 [35.3]	36.7 (35.1; 38.3)	218 [6.5]	673 [65.4]	347 [52.6]	1,238 [20.7]	19.7 (18.6; 20.8)
	X/NA	10 [0.3]	33 [3.4]	30 [6.5]	73 [1.3]	1.3 (1.0; 1.6)	6 [0.2]	19 [1.8]	20 [3.0]	45 [0.8]	0.7 (0.5; 0.9)
SCC	**I**	18 [0.5]	160 [16.4]	141 [30.6]	319 [5.5]	5.8 (5.2; 6.4)	8 [0.2]	90 [8.7]	58 [8.8]	156 [2.6]	2.5 (2.1; 2.9)
	II	14 [0.4]	93 [9.6]	63 [13.7]	170 [2.9]	3.1 (2.6; 3.5)	5 [0.1]	41 [4.0]	18 [2.7]	64 [1.1]	1.0 (0.8; 1.3)
	III	35 [1.0]	216 [22.2]	147 [31.9]	398 [6.9]	7.1 (6.4; 7.9)	11 [0.3]	93 [9.0]	43 [6.5]	147 [2.5]	2.3 (1.9; 2.7)
	IV	41 [1.2]	243 [25.0]	201 [43.6]	485 [8.4]	8.8 (8.0; 9.5)	8 [0.2]	77 [7.5]	60 [9.1]	145 [2.4]	2.3 (1.9; 2.6)
	X/NA	3 [0.1]	15 [1.5]	8 [1.7]	26 [0.4]	0.5 (0.3; 0.6)	0 [0.0]	6 [0.6]	4 [0.6]	10 [0.2]	0.2 (0.1; 0.3)
ADC	**I**	95 [2.8]	366 [37.6]	193 [41.9]	654 [11.3]	11.6 (10.7; 12.5)	96 [2.9]	406 [39.4]	143 [21.7]	645 [10.8]	10.4 (9.6; 11.2)
	II	20 [0.6]	98 [10.1]	58 [12.6]	176 [3.0]	3.1 (2.7; 3.6)	23 [0.7]	85 [8.3]	36 [5.5]	144 [2.4]	2.3 (1.9; 2.7)
	III	66 [2.0]	175 [18.0]	118 [25.6]	359 [6.2]	6.4 (5.8; 7.1)	52 [1.6]	160 [15.5]	72 [10.9]	284 [4.8]	4.6 (4.0; 5.1)
	IV	248 [7.3]	679 [69.8]	458 [99.4]	1,385 [23.9]	24.8 (23.5; 26.1)	197 [5.9]	546 [53.0]	271 [41.1]	1,014 [17.0]	16.2 (15.2; 17.2)
	X/NA	6 [0.2]	12 [1.2]	16 [3.5]	34 [0.6]	0.6 (0.4; 0.8)	6 [0.2]	12 [1.2]	10 [1.5]	28 [0.5]	0.4 (0.3; 0.6)
LCC	**I**	2 [0.1]	9 [0.9]	4 [0.9]	15 [0.3]	0.3 (0.1; 0.4)	0 [0.0]	9 [0.9]	3 [0.5]	12 [0.2]	0.2 (0.1; 0.3)

Histological types	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
	II	1 [0.0]	6 [0.6]	1 [0.2]	8 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	2 [0.2]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)
	III	4 [0.1]	6 [0.6]	4 [0.9]	14 [0.2]	0.3 (0.1; 0.4)	0 [0.0]	5 [0.5]	1 [0.2]	6 [0.1]	0.1 (0.0; 0.2)
	IV	8 [0.2]	30 [3.1]	19 [4.1]	57 [1.0]	1.0 (0.8; 1.3)	4 [0.1]	15 [1.5]	4 [0.6]	23 [0.4]	0.4 (0.2; 0.5)
	X/NA	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Other NSCLC	**I**	4 [0.1]	14 [1.4]	10 [2.2]	28 [0.5]	0.5 (0.3; 0.7)	1 [0.0]	8 [0.8]	3 [0.5]	12 [0.2]	0.2 (0.1; 0.3)
	II	2 [0.1]	5 [0.5]	4 [0.9]	11 [0.2]	0.2 (0.1; 0.3)	0 [0.0]	3 [0.3]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)
	III	4 [0.1]	17 [1.7]	19 [4.1]	40 [0.7]	0.7 (0.5; 0.9)	2 [0.1]	11 [1.1]	9 [1.4]	22 [0.4]	0.3 (0.2; 0.5)
	IV	23 [0.7]	64 [6.6]	35 [7.6]	122 [2.1]	2.1 (1.8; 2.5)	9 [0.3]	35 [3.4]	12 [1.8]	56 [0.9]	0.9 (0.7; 1.1)
	X/NA	1 [0.0]	6 [0.6]	6 [1.3]	13 [0.2]	0.2 (0.1; 0.4)	0 [0.0]	1 [0.1]	6 [0.9]	7 [0.1]	0.1 (0.0; 0.2)
Other	**I**	35 [1.0]	152 [15.6]	240 [52.1]	428 [7.4]	7.9 (7.1; 8.6)	37 [1.1]	177 [17.2]	159 [24.1]	373 [6.3]	5.8 (5.2; 6.4)
	II	10 [0.3]	23 [2.4]	29 [6.3]	62 [1.1]	1.1 (0.9; 1.4)	6 [0.2]	9 [0.9]	20 [3.0]	35 [0.6]	0.5 (0.4; 0.7)
	III	1 [0.0]	25 [2.6]	38 [8.2]	64 [1.1]	1.2 (0.9; 1.5)	3 [0.1]	13 [1.3]	26 [3.9]	42 [0.7]	0.6 (0.4; 0.8)
	IV	17 [0.5]	48 [4.9]	121 [26.3]	186 [3.2]	3.5 (3.0; 4.0)	2 [0.1]	44 [4.3]	63 [9.6]	109 [1.8]	1.6 (1.3; 1.9)
	X/NA	1 [0.0]	13 [1.3]	12 [2.6]	26 [0.4]	0.5 (0.3; 0.7)	4 [0.1]	5 [0.5]	6 [0.9]	16 [0.3]	0.3 (0.1; 0.4)

2.1. Lung cancer incidence trends: by region

2.1.1. Lung cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	5,510	5,412	5,369	5,508	5,482	5,519	5,664	5,663	5,827	5,733	5,807	5,746	5,475	5,633	5,772	5,668	5,594	5,689	5,691	5,726	5,779		
	CR	108.3	105.9	104.4	106.3	105.0	104.8	106.6	105.5	107.6	105.2	106.1	104.4	98.9	101.2	103.1	100.7	98.8	100.2	99.7	99.4	99.7		
	ESR2013	135.2	131.5	128.3	128.6	125.9	125.0	127.7	125.7	126.8	123.2	122.9	119.5	112.3	113.7	114.9	110.7	107.3	108.2	106.4	105.1	104.0	-1.2 (-1.4; -1.1)	2004-2024
																							-0.9 (-1.2; -0.6)	2004-2015
																							-2.2 (-2.9; -1.4)	2016-2019
																							-1.1 (-1.9; -0.3)	2020-2024
Brussels	**N**	402	394	367	353	372	375	458	379	384	390	390	373	403	382	423	382	395	405	371	384	358		
	CR	83.7	81.5	74.9	71.1	73.6	72.6	86.9	69.9	69.5	69.4	68.8	65.1	69.5	65.6	72.1	64.5	66.1	67.6	61.8	63.1	58.5		
	ESR2013	120.4	117.2	108.7	105.5	108.8	108.5	134.6	109.1	105.9	111.1	107.9	102.4	111.4	105.0	112.4	100.8	104.8	105.1	95.8	98.6	89.6	-0.9 (-1.4; -0.4)	2004-2024
Flanders	**N**	3,269	3,187	3,254	3,350	3,286	3,269	3,375	3,372	3,452	3,424	3,449	3,399	3,221	3,273	3,406	3,304	3,276	3,364	3,337	3,316	3,320		
	CR	110.2	107.0	108.6	111.0	108.1	106.7	109.4	108.3	110.1	108.6	108.9	106.8	100.6	101.6	105.1	101.3	99.9	102.1	100.6	98.9	98.3		
	ESR2013	133.6	127.6	127.5	128.1	123.4	121.2	124.1	121.5	122.1	119.7	118.6	114.0	106.7	106.5	109.6	104.2	101.1	102.7	100.1	97.6	95.8	-1.5 (-1.7; -1.3)	2004-2024
																							-1.1 (-1.5; -0.8)	2004-2014
																							-2.5 (-3.4; -1.7)	2015-2018
																							-1.5 (-2.2; -0.9)	2019-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Wallonia	**N**	1,839	1,831	1,748	1,805	1,824	1,875	1,831	1,912	1,991	1,919	1,968	1,974	1,851	1,978	1,943	1,982	1,923	1,920	1,983	2,026	2,101		
	CR	112.1	111.1	105.5	108.2	108.7	111.1	107.7	111.5	115.4	110.6	113.0	112.8	105.4	112.1	109.8	111.6	107.9	107.6	110.7	112.5	116.2		
	ESR2013	142.0	143.2	135.0	135.4	135.2	135.9	132.4	138.1	140.6	132.1	134.6	134.1	122.9	129.8	124.4	125.1	119.4	118.7	120.1	120.4	122.6	-0.8 (-1.1; -0.6)	2004-2024
																							-0.6 (-1.9; 0.8)	2004-2008
																							-0.9 (-1.2; -0.6)	2009-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Lung cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	1,554	1,593	1,704	1,880	1,814	2,081	2,247	2,346	2,369	2,503	2,673	2,673	2,760	2,886	3,123	3,274	3,341	3,536	3,739	3,780	3,902		
	CR	29.3	29.9	31.7	34.8	33.3	37.9	40.6	42.0	42.1	44.3	47.1	46.9	48.2	50.2	54.0	56.4	57.3	60.5	63.6	63.7	65.4		
	ESR2013	30.5	31.0	32.8	35.8	34.4	39.1	41.5	43.1	42.9	45.1	47.3	46.8	48.2	49.7	53.1	55.1	55.6	58.4	60.9	60.6	61.8	3.8 (3.6; 4.0)	2004-2024
																							5.4 (4.6; 6.2)	2004-2010
																							3.2 (2.9; 3.5)	2011-2024
Brussels	**N**	185	163	189	194	170	203	211	223	221	238	222	237	228	238	258	248	243	246	253	266	267		
	CR	35.6	31.2	35.7	36.3	31.4	36.8	37.5	38.7	37.7	40.1	37.2	39.3	37.5	39.1	42.1	40.3	39.2	39.6	40.7	42.0	41.9		
	ESR2013	40.1	36.3	41.6	42.7	37.0	44.1	45.7	48.5	47.8	52.3	47.8	50.2	48.4	50.2	53.5	51.6	50.7	52.1	52.4	54.9	54.5	1.9 (1.5; 2.2)	2004-2024
																							3.2 (2.1; 4.3)	2004-2012
																							1.0 (0.3; 1.6)	2013-2024
Flanders	**N**	824	864	888	996	977	1,080	1,206	1,257	1,270	1,350	1,426	1,458	1,505	1,560	1,737	1,822	1,863	1,978	2,068	2,127	2,171		
	CR	27.0	28.2	28.8	32.1	31.3	34.3	38.1	39.4	39.5	41.8	43.9	44.7	45.9	47.3	52.4	54.7	55.6	58.9	61.1	62.1	63.0		
	ESR2013	27.6	28.4	29.0	32.1	31.3	34.1	37.5	38.8	38.5	40.7	42.2	42.9	43.9	44.8	49.5	50.9	51.8	54.3	56.0	56.5	57.1	4.0 (3.8; 4.2)	2004-2024
																							5.0 (4.3; 5.6)	2004-2011
																							3.4 (3.1; 3.8)	2012-2024
Wallonia	**N**	545	566	627	690	667	798	830	866	878	915	1,025	978	1,027	1,088	1,128	1,204	1,235	1,312	1,418	1,387	1,464		
	CR	31.3	32.4	35.7	39.0	37.5	44.6	46.2	47.8	48.2	50.0	55.9	53.2	55.7	58.8	60.8	64.8	66.3	70.4	75.8	73.7	77.7		
	ESR2013	33.2	34.4	37.6	40.9	39.2	46.8	48.0	49.7	49.7	51.4	56.8	52.9	56.1	58.7	59.9	63.7	64.0	67.6	72.1	69.5	72.3	4.1 (3.8; 4.4)	2004-2024
																							6.9 (5.6; 8.3)	2004-2009
																							3.2 (2.9; 3.6)	2010-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Lung cancer incidence trends: by tumour stage

2.2.1. Lung cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Stage		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
I	**N**	1,131	1,217	1,310	1,350	1,470			786	939	986	1,103	1,217		
	CR	20.0	21.4	22.9	23.4	25.4			13.5	16.1	16.8	18.6	20.4		
	ESR2013	21.8	23.2	24.6	24.7	26.6	2.0 (1.6; 2.4)	2004-2024	13.1	15.6	16.2	17.7	19.3	8.1 (7.7; 8.6)	2004-2024
II	**N**	409	444	453	478	449			229	232	296	288	272		
	CR	7.2	7.8	7.9	8.3	7.7			3.9	4.0	5.0	4.9	4.6		
	ESR2013	7.9	8.4	8.5	8.8	8.1	0.9 (0.3; 1.5)	2004-2024	3.9	3.9	4.8	4.6	4.3	6.5 (5.5; 7.5)	2004-2024
							5.6 (4.0; 7.3)	2004-2012						10.1 (7.5; 12.8)	2004-2013
							-2.1 (-3.1; -1.2)	2013-2024						3.7 (1.7; 5.7)	2014-2024
III	**N**	1,093	1,116	1,109	1,086	998			579	607	641	599	642		
	CR	19.3	19.7	19.4	18.8	17.2			9.9	10.4	10.9	10.1	10.8		
	ESR2013	20.8	21.2	20.7	19.9	18.0	-1.4 (-1.8; -1.0)	2004-2024	9.6	10.0	10.5	9.7	10.2	4.0 (3.4; 4.6)	2004-2024
							0.4 (-0.4; 1.3)	2004-2014						7.8 (5.5; 10.2)	2004-2010
							-3.2 (-4.0; -2.4)	2015-2024						3.4 (0.7; 6.3)	2011-2014
														1.9 (0.8; 3.1)	2015-2024
IV	**N**	2,748	2,787	2,668	2,687	2,746			1,619	1,675	1,733	1,699	1,705		
	CR	48.6	49.1	46.7	46.6	47.4			27.8	28.7	29.5	28.6	28.6		
	ESR2013	52.7	53.0	49.7	49.3	49.3	1.3 (1.0; 1.6)	2004-2024	26.9	27.6	28.1	27.2	27.0	5.7 (5.2; 6.1)	2004-2024
							3.3 (2.6; 4.0)	2004-2014						8.4 (7.4; 9.4)	2004-2014
							-0.6 (-1.3; 0.0)	2015-2024						3.0 (2.0; 3.9)	2015-2024
X/NA	**N**	213	125	151	125	116			128	83	83	91	66		

Stage	Males							Females						
	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
CR	3.8	2.2	2.6	2.2	2.0			2.2	1.4	1.4	1.5	1.1		
ESR2013	4.1	2.4	2.9	2.3	2.1	-15.1 (-16.1; -14.1)	2004-2024	2.1	1.3	1.4	1.4	1.0	-11.4 (-12.2; -10.5)	2004-2024
						-10.6 (-13.4; -7.7)	2004-2012						-6.4 (-8.9; -3.8)	2004-2012
						-17.9 (-22.3; -13.2)	2013-2016						-14.5 (-16.0; -13.1)	2013-2024
						-18.0 (-20.5; -15.3)	2017-2024							

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Lung cancer incidence trends: by age group

2.3.1. Lung cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	1,171	1,139	1,158	1,158	1,174	1,171	1,085	1,091	1,104	1,032	1,012	944	897	861	853	836	817	783	728	718	753		
	CR	36.7	35.5	35.9	35.8	36.1	35.8	33.1	33.0	33.3	31.0	30.4	28.4	26.9	25.8	25.6	25.1	24.5	23.4	21.7	21.3	22.3		
	ESR2013	39.7	37.7	37.7	37.4	37.7	37.3	34.2	33.9	33.8	31.3	30.4	28.0	26.3	25.2	24.8	24.3	23.6	22.7	21.1	20.9	22.0	-3.4 (-3.8; -3.1)	2004-2024
60-74	**N**	2,707	2,646	2,547	2,652	2,572	2,578	2,659	2,664	2,780	2,736	2,813	2,863	2,736	2,894	2,976	2,943	2,915	2,900	2,923	2,975	2,862		
	CR	397.8	386.3	370.8	378.9	360.9	354.5	358.7	352.4	361.4	349.3	353.1	352.3	328.6	337.8	338.5	327.6	317.9	310.3	309.2	310.2	294.0		
	ESR2013	395.5	385.0	370.7	381.9	367.0	362.4	367.6	362.9	371.2	359.6	363.2	361.8	338.7	346.4	345.1	333.1	323.6	315.4	315.1	317.2	300.6	-1.2 (-1.3; -1.0)	2004-2024
																							-0.7 (-1.0; -0.4)	2004-2015
																							-1.7 (-2.1; -1.4)	2016-2024
75+	**N**	1,632	1,627	1,663	1,698	1,734	1,770	1,920	1,908	1,942	1,965	1,981	1,937	1,842	1,877	1,943	1,889	1,862	2,004	2,039	2,033	2,163		
	CR	556.7	537.5	529.5	521.2	514.9	512.2	542.3	528.2	526.1	522.5	516.6	494.8	466.6	475.4	489.1	467.5	450.3	481.6	472.9	456.6	469.6		
	ESR2013	519.5	510.2	500.6	485.6	481.4	482.2	523.0	511.4	508.9	505.7	502.2	481.9	455.6	464.2	482.2	461.5	444.9	475.5	466.8	449.8	461.5	-0.6 (-0.8; -0.4)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Lung cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	540	547	600	623	588	710	734	690	727	720	695	680	709	684	646	722	644	647	684	589	546		
	CR	17.2	17.4	18.9	19.5	18.4	22.1	22.7	21.2	22.2	22.0	21.2	20.7	21.6	20.8	19.7	22.0	19.6	19.7	20.8	17.7	16.3		
	ESR2013	18.1	18.1	19.5	20.0	18.8	22.5	23.0	21.3	22.2	21.8	20.9	20.2	21.0	20.2	19.0	21.2	19.0	19.1	20.2	17.4	16.2	0.0 (-0.5; 0.5)	2004-2024
																							3.9 (2.0; 5.8)	2004-2010
																							-1.0 (-3.2; 1.2)	2011-2014
																							-1.9 (-2.8; -1.0)	2015-2024
60-74	**N**	627	642	688	784	796	875	954	1,073	1,059	1,190	1,281	1,289	1,365	1,496	1,669	1,700	1,855	1,930	2,043	2,117	2,177		
	CR	80.9	82.8	89.1	100.5	101.0	109.4	117.8	130.4	126.9	140.5	149.3	147.8	153.0	163.0	177.5	177.3	189.8	194.1	203.4	208.1	211.5		
	ESR2013	80.9	83.1	88.7	100.4	101.3	110.4	118.2	131.6	127.6	141.4	149.7	148.1	154.4	163.9	178.3	178.0	190.5	194.9	204.4	209.3	212.9	5.2 (5.0; 5.4)	2004-2024
																							6.8 (6.2; 7.4)	2004-2012
																							4.1 (3.8; 4.5)	2013-2024
75+	**N**	387	404	415	473	430	496	559	583	583	592	697	704	686	704	807	852	842	959	1,012	1,074	1,178		
	CR	74.4	76.1	76.2	84.9	75.5	85.8	95.3	98.3	97.2	98.0	114.2	114.1	111.3	114.9	132.0	138.7	135.7	154.9	159.6	166.4	178.7		
	ESR2013	73.2	74.8	75.5	84.1	73.9	84.9	95.3	99.3	98.5	100.1	115.7	116.6	115.6	120.7	140.0	148.2	145.8	168.1	170.7	176.5	190.5	5.1 (4.7; 5.5)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Lung cancer incidence trends: by histological type

2.4.1. Lung cancer incidence trends in males, by histological type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Histological type		2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
SCLC	**N**	854	785	698	750	781	742	738	683	716	714	699			
	CR	15.6	14.3	12.6	13.5	14.0	13.2	13.0	12.0	12.5	12.4	12.1			
	ESR2013	17.9	16.1	14.1	15.0	15.4	14.4	14.0	12.8	13.2	13.0	12.5	-2.3	(-2.7; -1.9)	2004-2024
													-1.1	(-2.7; 0.6)	2004-2010
													-2.5	(-4.5; -0.6)	2011-2014
													-3.0	(-3.8; -2.2)	2015-2024
NSCLC	**N**	4,311	4,379	4,191	4,255	4,371	4,253	4,129	4,275	4,192	4,229	4,314			
	CR	78.7	79.5	75.7	76.4	78.1	75.6	72.9	75.3	73.4	73.4	74.4			
	ESR2013	90.4	90.4	85.5	85.3	86.4	82.6	78.6	80.9	77.9	77.2	77.3	-1.4	(-1.5; -1.3)	2004-2024
													-0.8	(-1.1; -0.5)	2004-2012
													-1.8	(-2.0; -1.6)	2013-2024
SCC	**N**	1,667	1,622	1,515	1,621	1,634	1,520	1,421	1,483	1,495	1,480	1,398			
	CR	30.5	29.5	27.4	29.1	29.2	27.0	25.1	26.1	26.2	25.7	24.1			
	ESR2013	35.4	33.9	31.3	33.0	32.8	30.0	27.3	28.3	28.0	27.2	25.2	-2.9	(-3.1; -2.6)	2004-2024
ADC	**N**	2,330	2,411	2,311	2,352	2,417	2,439	2,437	2,502	2,418	2,443	2,608			
	CR	42.6	43.8	41.7	42.2	43.2	43.3	43.1	44.1	42.4	42.4	45.0			
	ESR2013	48.3	49.2	46.7	46.7	47.3	46.9	46.2	47.1	44.7	44.4	46.6	1.1	(0.9; 1.2)	2004-2024
													3.3	(2.9; 3.7)	2004-2013
													-0.7	(-1.0; -0.4)	2014-2024
LCC	**N**	145	165	134	100	104	105	116	122	104	104	94			
	CR	2.6	3.0	2.4	1.8	1.9	1.9	2.0	2.1	1.8	1.8	1.6			

Histological type		2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
	ESR2013	3.1	3.4	2.7	2.0	2.1	2.1	2.2	2.3	1.9	1.9	1.7	-6.8	(-8.0; -5.6)	2004-2024
													-7.8	(-9.1; -6.5)	2004-2020
													-2.4	(-9.0; 4.7)	2021-2024
Other NSCLC	**N**	169	181	231	182	216	189	155	168	175	202	214			
	CR	3.1	3.3	4.2	3.3	3.9	3.4	2.7	3.0	3.1	3.5	3.7			
	ESR2013	3.6	3.9	4.8	3.6	4.3	3.7	3.0	3.2	3.2	3.7	3.8	-6.3	(-7.4; -5.2)	2004-2024
													-10.2	(-12.5; -7.8)	2004-2014
													-2.3	(-4.9; 0.3)	2015-2024
Other	**N**	642	582	586	628	620	673	727	731	783	783	766			
	CR	11.7	10.6	10.6	11.3	11.1	12.0	12.8	12.9	13.7	13.6	13.2			
	ESR2013	14.6	12.9	12.7	13.4	13.0	13.7	14.6	14.5	15.3	14.9	14.2	1.2	(0.5; 1.9)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4.2. Lung cancer incidence trends in females, by histological type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Histological type		2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
SCLC	**N**	451	397	394	408	470	491	486	497	506	477	544			
	CR	7.9	7.0	6.9	7.1	8.1	8.5	8.3	8.5	8.6	8.0	9.1			
	ESR2013	8.1	7.1	7.0	7.1	8.1	8.4	8.2	8.3	8.3	7.7	8.7	2.3	(1.9; 2.8)	2004-2024
NSCLC	**N**	1,925	1,939	1,992	2,127	2,276	2,370	2,359	2,519	2,716	2,728	2,783			
	CR	33.9	34.0	34.8	37.0	39.4	40.8	40.4	43.1	46.2	46.0	46.6			
	ESR2013	34.3	34.1	35.0	36.9	38.9	40.2	39.5	41.9	44.5	44.0	44.4	3.8	(3.5; 4.1)	2004-2024
													6.0	(4.9; 7.1)	2004-2010
													2.8	(2.4; 3.2)	2011-2024
SCC	**N**	367	343	395	427	462	473	436	470	514	511	522			
	CR	6.5	6.0	6.9	7.4	8.0	8.2	7.5	8.0	8.7	8.6	8.7			
	ESR2013	6.6	6.1	7.1	7.4	7.9	8.0	7.3	7.8	8.4	8.3	8.2	2.4	(1.9; 2.9)	2004-2024
ADC	**N**	1,448	1,470	1,457	1,588	1,676	1,759	1,798	1,898	2,043	2,069	2,115			
	CR	25.5	25.8	25.4	27.6	29.0	30.3	30.8	32.5	34.8	34.9	35.4			
	ESR2013	25.7	25.8	25.5	27.5	28.6	29.8	30.1	31.6	33.5	33.4	33.8	5.1	(4.7; 5.4)	2004-2024
													8.0	(6.9; 9.0)	2004-2012
													3.2	(2.5; 3.8)	2013-2024
LCC	**N**	45	60	54	46	56	45	51	55	58	48	45			
	CR	0.8	1.1	0.9	0.8	1.0	0.8	0.9	0.9	1.0	0.8	0.8			
	ESR2013	0.8	1.1	0.9	0.8	0.9	0.8	0.9	0.9	1.0	0.8	0.7	-3.4	(-4.4; -2.3)	2004-2024

Histological type		2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
Other NSCLC	**N**	65	66	86	66	82	93	74	96	101	100	101			
	CR	1.1	1.2	1.5	1.1	1.4	1.6	1.3	1.6	1.7	1.7	1.7			
	ESR2013	1.2	1.2	1.5	1.1	1.4	1.6	1.3	1.6	1.6	1.6	1.6	-2.4	(-3.9; -0.9)	2004-2024
													-6.2	(-8.8; -3.6)	2004-2016
													3.7	(-0.8; 8.3)	2017-2024
Other	**N**	297	337	374	351	377	413	496	520	517	575	575			
	CR	5.2	5.9	6.5	6.1	6.5	7.1	8.5	8.9	8.8	9.7	9.6			
	ESR2013	4.9	5.6	6.1	5.7	6.1	6.5	8.0	8.2	8.2	8.8	8.8	6.3	(5.7; 6.8)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Lung cancer prevalence: by region

3.1.1. Lung cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	4,057	11,569	15,356	16,845	17,604	2,957	9,133	12,253	13,545	14,157
	CR	69.6	198.4	263.4	288.9	302.0	49.3	152.3	204.4	225.9	236.1
	ESR2013	71.5	204.3	271.7	298.6	312.4	46.4	142.9	191.2	210.8	220.1
Brussels	**N**	249	762	1,022	1,117	1,167	192	596	855	955	1,004
	CR	40.5	123.8	166.1	181.5	189.6	30.0	93.1	133.5	149.1	156.8
	ESR2013	61.2	186.6	252.4	276.4	289.4	38.9	121.3	173.3	193.3	203.1
Flanders	**N**	2,345	6,709	8,973	9,850	10,306	1,700	5,193	6,908	7,620	7,964
	CR	69.0	197.3	263.9	289.7	303.1	49.1	149.9	199.4	219.9	229.8
	ESR2013	66.3	190.0	254.3	279.3	292.5	44.3	134.8	178.6	196.5	205.1
Wallonia	**N**	1,463	4,098	5,361	5,878	6,131	1,065	3,344	4,490	4,970	5,189
	CR	80.6	225.8	295.4	323.9	337.8	56.3	176.9	237.5	262.9	274.5
	ESR2013	83.5	234.5	308.1	338.9	354.4	52.1	163.3	219.0	241.9	252.4

4.1. Lung cancer survival: by region

4.1.1. Lung cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024				
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
		87,812	56.5% (56.1%; 56.8%)	35.9% (35.5%; 36.2%)	28.4% (28.0%; 28.7%)	18.6% (17.9%; 19.3%)
Males						
Belgium	**All ages 15+**	55,611	53.6% (53.1%; 54.0%)	32.5% (32.1%; 33.0%)	25.1% (24.6%; 25.5%)	15.5% (14.7%; 16.3%)
	15-59	8,063	60.5% (59.4%; 61.6%)	38.9% (37.8%; 40.0%)	31.6% (30.5%; 32.8%)	23.3% (21.9%; 24.7%)
	60-74	28,380	57.3% (56.7%; 57.9%)	35.6% (35.0%; 36.2%)	27.9% (27.3%; 28.5%)	17.5% (16.7%; 18.4%)
	75+	19,319	45.2% (44.5%; 46.0%)	25.4% (24.6%; 26.1%)	18.0% (17.2%; 18.9%)	8.8% (7.2%; 10.6%)
Brussels	**All ages 15+**	3,785	54.8% (53.2%; 56.5%)	33.1% (31.4%; 34.8%)	26.1% (24.4%; 28.0%)	16.9% (14.0%; 20.4%)
	15-59	869	62.1% (58.9%; 65.5%)	43.3% (40.0%; 46.8%)	35.8% (32.5%; 39.6%)	27.0% (22.3%; 32.7%)
	60-74	1,822	56.9% (54.6%; 59.3%)	33.0% (30.8%; 35.5%)	26.2% (23.9%; 28.8%)	18.3% (15.2%; 21.9%)
	75+	1,106	45.8% (42.7%; 49.0%)	25.3% (22.3%; 28.7%)	18.6% (15.4%; 22.5%)	7.4% (3.5%; 15.8%)
Flanders	**All ages 15+**	32,577	53.4% (52.8%; 53.9%)	32.1% (31.5%; 32.7%)	24.8% (24.3%; 25.4%)	15.7% (14.7%; 16.7%)
	15-59	3,840	61.9% (60.4%; 63.5%)	40.5% (38.9%; 42.1%)	33.5% (31.9%; 35.1%)	26.0% (24.1%; 28.0%)
	60-74	16,151	57.7% (57.0%; 58.5%)	35.6% (34.9%; 36.4%)	27.9% (27.1%; 28.7%)	17.9% (16.8%; 19.0%)
	75+	12,674	45.3% (44.4%; 46.2%)	25.1% (24.2%; 26.0%)	18.2% (17.2%; 19.2%)	9.2% (7.3%; 11.6%)
Wallonia	**All ages 15+**	19,259	53.6% (52.9%; 54.4%)	33.1% (32.4%; 33.9%)	25.2% (24.4%; 26.0%)	14.8% (13.5%; 16.1%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	15-59	3,354	58.5% (56.8%; 60.2%)	35.9% (34.2%; 37.6%)	28.4% (26.8%; 30.1%)	18.9% (16.8%; 21.2%)
	60-74	10,410	56.8% (55.8%; 57.7%)	36.1% (35.1%; 37.1%)	28.2% (27.2%; 29.3%)	16.8% (15.3%; 18.5%)
	75+	5,540	45.0% (43.6%; 46.4%)	26.0% (24.6%; 27.5%)	17.5% (16.0%; 19.2%)	8.1% (5.6%; 11.6%)
Females						
Belgium	**All ages 15+**	32,201	61.5% (61.0%; 62.1%)	41.7% (41.1%; 42.3%)	34.1% (33.5%; 34.8%)	24.3% (23.2%; 25.5%)
	15-59	6,424	69.5% (68.3%; 70.6%)	48.8% (47.5%; 50.0%)	41.6% (40.3%; 42.9%)	33.4% (31.8%; 35.1%)
	60-74	17,188	63.6% (62.9%; 64.3%)	43.7% (42.9%; 44.5%)	35.6% (34.8%; 36.5%)	24.0% (22.8%; 25.3%)
	75+	8,703	51.7% (50.6%; 52.8%)	32.7% (31.5%; 33.8%)	25.6% (24.3%; 27.0%)	17.0% (13.9%; 20.8%)
Brussels	**All ages 15+**	2,414	61.2% (59.2%; 63.2%)	40.1% (38.1%; 42.4%)	33.3% (31.1%; 35.7%)	24.2% (21.0%; 28.0%)
	15-59	508	68.4% (64.5%; 72.6%)	46.1% (41.9%; 50.9%)	40.4% (36.0%; 45.3%)	33.0% (27.6%; 39.5%)
	60-74	1,181	61.9% (59.2%; 64.8%)	41.9% (39.0%; 45.0%)	35.8% (32.8%; 39.0%)	26.6% (22.7%; 31.3%)
	75+	731	55.1% (51.4%; 59.1%)	33.3% (29.5%; 37.7%)	24.5% (20.5%; 29.3%)	15.4% (9.6%; 24.8%)
Flanders	**All ages 15+**	17,883	61.9% (61.1%; 62.6%)	41.7% (40.9%; 42.5%)	34.1% (33.2%; 34.9%)	25.3% (24.0%; 26.7%)
	15-59	3,248	69.1% (67.5%; 70.7%)	48.2% (46.5%; 50.0%)	40.9% (39.2%; 42.8%)	33.7% (31.6%; 36.0%)
	60-74	9,536	64.9% (63.9%; 65.8%)	44.3% (43.3%; 45.4%)	36.2% (35.1%; 37.3%)	24.6% (22.9%; 26.4%)
	75+	5,156	52.0% (50.5%; 53.4%)	32.8% (31.3%; 34.4%)	25.8% (24.1%; 27.6%)	20.2% (17.0%; 24.0%)
Wallonia	**All ages 15+**	11,909	61.1% (60.2%; 62.0%)	42.0% (41.0%; 42.9%)	34.4% (33.4%; 35.4%)	22.9% (20.7%; 25.3%)
	15-59	2,668	70.1% (68.4%; 71.9%)	49.9% (48.0%; 51.9%)	42.5% (40.5%; 44.6%)	33.3% (30.7%; 36.0%)
	60-74	6,475	62.1% (60.9%; 63.3%)	43.0% (41.7%; 44.3%)	34.8% (33.4%; 36.2%)	22.7% (20.7%; 24.8%)
	75+	2,816	50.3% (48.4%; 52.3%)	32.2% (30.2%; 34.4%)	25.5% (23.2%; 27.9%)	12.0% (6.8%; 21.2%)

4.2. Lung cancer survival: by histological type and tumour stage

4.2.1. Lung cancer survival by histological type, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Type	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All**	87,812	56.5% (56.1%; 56.8%)	42.8% (42.4%; 43.1%)	35.9% (35.5%; 36.2%)	31.5% (31.1%; 31.9%)	28.4% (28.0%; 28.7%)	18.6% (17.9%; 19.3%)
Males								
Lung	**All**	55,611	53.6% (53.1%; 54.0%)	39.5% (39.1%; 39.9%)	32.5% (32.1%; 33.0%)	28.2% (27.8%; 28.6%)	25.1% (24.6%; 25.5%)	15.5% (14.7%; 16.3%)
	I	11,142	90.1% (89.4%; 90.7%)	79.6% (78.7%; 80.5%)	71.6% (70.6%; 72.7%)	64.8% (63.6%; 66.0%)	58.7% (57.3%; 60.0%)	37.0% (34.4%; 39.9%)
	II	4,039	78.7% (77.3%; 80.1%)	63.2% (61.5%; 64.9%)	53.6% (51.8%; 55.5%)	47.3% (45.4%; 49.3%)	42.8% (40.8%; 44.9%)	27.4% (23.1%; 32.5%)
	III	11,059	61.8% (60.9%; 62.8%)	43.1% (42.1%; 44.1%)	33.4% (32.5%; 34.4%)	28.1% (27.1%; 29.1%)	24.8% (23.9%; 25.9%)	14.9% (13.5%; 16.5%)
	IV	26,310	31.7% (31.1%; 32.2%)	17.8% (17.3%; 18.3%)	12.5% (12.1%; 13.0%)	9.9% (9.5%; 10.3%)	8.1% (7.7%; 8.6%)	4.3% (3.8%; 4.9%)
	X/NA	3,649	48.7% (47.0%; 50.4%)	37.8% (36.2%; 39.5%)	32.9% (31.3%; 34.6%)	28.7% (27.1%; 30.5%)	26.1% (24.5%; 27.9%)	17.1% (14.6%; 19.9%)
SCLC	**All**	7,282	34.4% (33.3%; 35.6%)	15.9% (15.1%; 16.8%)	11.2% (10.5%; 12.0%)	9.0% (8.2%; 9.7%)	7.8% (7.1%; 8.6%)	4.5% (3.7%; 5.6%)
	I	262	82.1% (77.1%; 87.3%)	54.7% (48.5%; 61.7%)	42.9% (36.6%; 50.2%)	34.5% (28.2%; 42.2%)	30.9% (24.4%; 39.1%)	12.5% (6.8%; 23.1%)
	II	209	78.2% (72.4%; 84.4%)	50.1% (43.3%; 57.9%)	43.1% (36.3%; 51.2%)	36.9% (30.0%; 45.3%)	30.3% (23.6%; 39.0%)	18.5% (9.1%; 37.4%)
	III	1,479	57.5% (55.0%; 60.2%)	32.3% (29.9%; 34.9%)	24.2% (22.0%; 26.7%)	19.0% (16.8%; 21.3%)	17.3% (15.2%; 19.7%)	11.0% (8.5%; 14.2%)
	IV	4,881	24.2% (23.0%; 25.5%)	8.1% (7.3%; 8.9%)	4.6% (4.0%; 5.3%)	3.6% (3.1%; 4.3%)	3.0% (2.5%; 3.7%)	1.8% (1.1%; 2.8%)
	X/NA	451	21.3% (17.7%; 25.5%)	8.7% (6.4%; 11.9%)	6.2% (4.3%; 9.1%)	5.4% (3.6%; 8.2%)	4.4% (2.7%; 7.1%)	2.5% (1.2%; 5.1%)
NSCLC	**All**	41,921	56.9% (56.4%; 57.4%)	43.2% (42.7%; 43.7%)	35.8% (35.3%; 36.3%)	31.2% (30.7%; 31.7%)	27.9% (27.4%; 28.4%)	17.7% (16.8%; 18.6%)
	I	8,177	91.4% (90.7%; 92.2%)	82.5% (81.6%; 83.5%)	75.2% (74.1%; 76.4%)	69.0% (67.7%; 70.4%)	63.1% (61.6%; 64.6%)	43.2% (40.2%; 46.3%)
	II	3,331	80.4% (78.9%; 81.9%)	66.2% (64.4%; 68.0%)	56.8% (54.9%; 58.8%)	50.5% (48.4%; 52.7%)	46.2% (44.0%; 48.5%)	29.1% (24.3%; 34.9%)
	III	8,707	64.9% (63.9%; 66.0%)	46.9% (45.8%; 48.0%)	36.7% (35.6%; 37.8%)	31.1% (30.0%; 32.3%)	27.5% (26.4%; 28.7%)	16.0% (14.3%; 17.9%)
	IV	19,324	35.4% (34.8%; 36.1%)	21.4% (20.8%; 22.0%)	15.3% (14.7%; 15.8%)	12.1% (11.5%; 12.6%)	10.0% (9.5%; 10.6%)	5.3% (4.6%; 6.1%)
	X/NA	2,700	52.0% (50.0%; 54.0%)	41.6% (39.7%; 43.6%)	36.1% (34.2%; 38.1%)	31.6% (29.6%; 33.6%)	28.8% (26.8%; 30.8%)	19.1% (16.8%; 21.6%)

Net Survival Probability, 2015-2024										
Type	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
SCC	**All**	15,135	59.4% (58.6%; 60.2%)	43.8% (42.9%; 44.6%)	35.3% (34.5%; 36.2%)	30.2% (29.4%; 31.1%)	26.4% (25.6%; 27.3%)	16.1% (14.8%; 17.5%)
	I	3,048	88.6% (87.3%; 89.9%)	77.1% (75.3%; 78.8%)	69.1% (67.1%; 71.2%)	61.7% (59.5%; 64.0%)	54.1% (51.7%; 56.6%)	34.9% (30.7%; 39.7%)
	II	1,648	79.0% (76.9%; 81.2%)	63.0% (60.4%; 65.7%)	50.9% (48.2%; 53.8%)	44.6% (41.7%; 47.6%)	40.2% (37.2%; 43.4%)	26.7% (22.2%; 32.1%)
	III	4,572	62.3% (60.9%; 63.8%)	43.4% (41.9%; 45.0%)	32.5% (31.1%; 34.1%)	27.1% (25.6%; 28.6%)	23.8% (22.3%; 25.4%)	12.9% (10.8%; 15.4%)
	IV	4,873	34.1% (32.8%; 35.5%)	18.0% (16.9%; 19.2%)	12.1% (11.2%; 13.2%)	9.1% (8.2%; 10.1%)	7.2% (6.3%; 8.2%)	3.6% (2.5%; 5.3%)
	X/NA	1,002	48.4% (45.3%; 51.7%)	37.9% (34.9%; 41.3%)	32.5% (29.5%; 35.9%)	27.7% (24.7%; 31.0%)	24.7% (21.7%; 28.1%)	14.6% (11.5%; 18.5%)
ADC	**All**	24,077	57.5% (56.9%; 58.2%)	44.9% (44.2%; 45.6%)	37.9% (37.2%; 38.6%)	33.4% (32.7%; 34.1%)	30.1% (29.4%; 30.8%)	19.5% (18.3%; 20.9%)
	I	4,828	93.9% (93.1%; 94.7%)	87.2% (86.1%; 88.4%)	80.1% (78.7%; 81.6%)	74.9% (73.2%; 76.6%)	69.7% (67.8%; 71.7%)	50.5% (46.5%; 54.9%)
	II	1,516	83.8% (81.8%; 85.9%)	71.7% (69.2%; 74.3%)	65.5% (62.7%; 68.4%)	59.1% (56.0%; 62.3%)	54.2% (50.9%; 57.6%)	32.4% (23.8%; 44.1%)
	III	3,565	70.0% (68.5%; 71.6%)	52.6% (50.9%; 54.4%)	42.9% (41.1%; 44.8%)	36.6% (34.8%; 38.5%)	32.4% (30.5%; 34.3%)	19.8% (17.0%; 22.9%)
	IV	12,818	37.4% (36.6%; 38.3%)	23.6% (22.9%; 24.4%)	17.2% (16.5%; 17.9%)	13.8% (13.1%; 14.5%)	11.5% (10.8%; 12.2%)	5.9% (5.0%; 6.9%)
	X/NA	1,449	57.5% (54.9%; 60.2%)	47.3% (44.7%; 50.2%)	41.5% (38.8%; 44.4%)	36.9% (34.2%; 39.8%)	34.1% (31.4%; 37.1%)	23.7% (20.3%; 27.6%)
LCC	**All**	1,146	40.3% (37.5%; 43.3%)	28.2% (25.6%; 31.1%)	23.4% (20.9%; 26.2%)	20.5% (18.0%; 23.4%)	19.9% (17.3%; 22.9%)	10.3% (6.8%; 15.6%)
	I	140	85.2% (79.0%; 91.8%)	71.3% (63.4%; 80.1%)	65.1% (56.5%; 74.9%)	60.7% (51.3%; 71.8%)	57.8% (47.7%; 69.9%)	22.9% (11.1%; 47.3%)
	II	66	71.8% (61.3%; 84.0%)	62.2% (50.8%; 76.0%)	51.5% (39.7%; 66.8%)	43.6% (31.6%; 60.1%)	42.3% (29.9%; 59.9%)	26.0% (9.9%; 68.4%)
	III	216	53.7% (47.3%; 61.0%)	39.1% (32.8%; 46.6%)	32.5% (26.4%; 40.1%)	31.6% (25.3%; 39.4%)	30.1% (23.6%; 38.4%)	FU<10y
	IV	654	22.9% (19.8%; 26.4%)	11.7% (9.4%; 14.6%)	8.4% (6.4%; 11.0%)	5.1% (3.5%; 7.5%)	5.3% (3.6%; 7.7%)	4.4% (2.6%; 7.3%)
	X/NA	70	42.7% (32.4%; 56.4%)	31.1% (21.6%; 44.8%)	26.9% (17.8%; 40.6%)	26.9% (17.8%; 40.6%)	26.2% (17.1%; 40.0%)	21.7% (12.5%; 37.7%)
Other NSCLC	**All**	1,910	40.4% (38.2%; 42.7%)	28.6% (26.5%; 30.8%)	23.3% (21.3%; 25.5%)	20.2% (18.2%; 22.5%)	18.2% (16.1%; 20.5%)	12.0% (9.4%; 15.4%)
	I	233	81.7% (76.4%; 87.4%)	65.9% (59.3%; 73.2%)	59.3% (52.1%; 67.5%)	49.4% (41.6%; 58.7%)	46.4% (37.8%; 57.0%)	22.3% (12.5%; 39.9%)
	II	116	59.3% (50.6%; 69.5%)	42.4% (33.7%; 53.4%)	35.5% (26.7%; 47.2%)	32.9% (24.1%; 45.0%)	34.0% (24.9%; 46.5%)	FU<10y
	III	374	53.9% (48.9%; 59.4%)	39.3% (34.4%; 44.9%)	31.0% (26.3%; 36.6%)	28.9% (24.1%; 34.5%)	25.6% (20.8%; 31.5%)	20.4% (14.4%; 28.8%)
	IV	996	24.5% (21.9%; 27.4%)	14.9% (12.8%; 17.5%)	11.1% (9.2%; 13.5%)	9.5% (7.6%; 11.8%)	8.2% (6.3%; 10.6%)	6.1% (3.8%; 9.7%)
	X/NA	192	35.0% (28.8%; 42.7%)	24.2% (18.6%; 31.5%)	20.3% (15.0%; 27.4%)	15.7% (10.9%; 22.6%)	12.3% (7.9%; 19.2%)	7.6% (3.7%; 15.7%)

Net Survival Probability, 2015-2024													
Type	**cStage**	**N at risk**	**1-y (95%CI)**		**2-y (95%CI)**		**3-y (95%CI)**		**4-y (95%CI)**		**5-y (95%CI)**		**10-y (95%CI)**	
Other	**All**	6,821	54.3%	(53.0%; 55.5%)	42.3%	(41.0%; 43.7%)	35.4%	(34.1%; 36.8%)	30.3%	(28.9%; 31.8%)	26.0%	(24.5%; 27.6%)	12.5%	(9.6%; 16.2%)
	I	2,803	86.8%	(85.4%; 88.3%)	73.2%	(71.2%; 75.2%)	63.3%	(61.0%; 65.7%)	54.9%	(52.2%; 57.6%)	47.7%	(44.8%; 50.8%)	17.5%	(12.1%; 25.2%)
	II	507	67.5%	(63.1%; 72.2%)	48.9%	(44.1%; 54.2%)	36.4%	(31.5%; 42.1%)	30.0%	(24.9%; 36.1%)	25.1%	(19.8%; 31.9%)	21.4%	(13.9%; 33.0%)
	III	887	39.0%	(35.7%; 42.6%)	24.1%	(21.1%; 27.4%)	16.8%	(14.1%; 20.0%)	13.2%	(10.7%; 16.4%)	10.7%	(8.2%; 14.1%)	10.5%	(7.4%; 14.9%)
	IV	2,126	14.2%	(12.7%; 15.8%)	7.4%	(6.3%; 8.7%)	5.2%	(4.2%; 6.4%)	4.4%	(3.4%; 5.6%)	2.8%	(1.9%; 4.1%)	1.1%	(0.4%; 2.8%)
	X/NA	505	55.8%	(51.3%; 60.6%)	43.7%	(39.2%; 48.8%)	39.9%	(35.2%; 45.3%)	34.9%	(30.0%; 40.6%)	32.1%	(27.0%; 38.2%)	19.4%	(10.0%; 37.7%)
Females														
Lung	**All**	32,201	61.5%	(61.0%; 62.1%)	48.5%	(47.9%; 49.1%)	41.7%	(41.1%; 42.3%)	37.2%	(36.6%; 37.8%)	34.1%	(33.5%; 34.8%)	24.3%	(23.2%; 25.5%)
	I	7,935	93.5%	(92.9%; 94.1%)	86.6%	(85.7%; 87.4%)	80.9%	(79.8%; 81.9%)	75.6%	(74.4%; 76.9%)	71.4%	(70.0%; 72.8%)	52.0%	(47.7%; 56.7%)
	II	2,065	83.4%	(81.7%; 85.1%)	71.2%	(69.1%; 73.4%)	63.0%	(60.6%; 65.4%)	56.2%	(53.7%; 58.9%)	51.6%	(48.9%; 54.5%)	33.6%	(28.5%; 39.7%)
	III	5,560	66.5%	(65.3%; 67.8%)	48.1%	(46.8%; 49.5%)	39.1%	(37.7%; 40.5%)	33.9%	(32.5%; 35.3%)	30.3%	(28.9%; 31.8%)	19.0%	(17.1%; 21.1%)
	IV	15,039	40.3%	(39.5%; 41.1%)	25.4%	(24.7%; 26.1%)	18.8%	(18.2%; 19.5%)	15.2%	(14.6%; 15.9%)	13.0%	(12.4%; 13.7%)	7.9%	(7.1%; 8.9%)
	X/NA	2,005	60.6%	(58.5%; 62.9%)	51.2%	(48.9%; 53.5%)	46.0%	(43.7%; 48.4%)	43.2%	(40.8%; 45.7%)	40.6%	(38.2%; 43.2%)	35.2%	(32.0%; 38.6%)
SCLC	**All**	4,656	42.7%	(41.3%; 44.1%)	23.2%	(22.0%; 24.5%)	16.8%	(15.7%; 18.0%)	13.7%	(12.6%; 14.8%)	11.9%	(10.9%; 13.0%)	7.7%	(6.4%; 9.2%)
	I	190	85.4%	(80.3%; 90.9%)	65.6%	(58.9%; 73.2%)	53.1%	(45.9%; 61.4%)	43.8%	(36.4%; 52.6%)	37.0%	(29.3%; 46.6%)	15.0%	(6.5%; 34.7%)
	II	159	79.2%	(72.9%; 86.0%)	59.8%	(52.4%; 68.4%)	51.5%	(43.7%; 60.6%)	42.1%	(34.1%; 52.1%)	39.0%	(30.8%; 49.5%)	15.5%	(7.6%; 31.6%)
	III	1,144	64.2%	(61.4%; 67.1%)	39.4%	(36.6%; 42.4%)	29.8%	(27.1%; 32.7%)	24.4%	(21.7%; 27.3%)	21.7%	(19.1%; 24.7%)	13.9%	(10.9%; 17.8%)
	IV	2,922	30.3%	(28.6%; 32.0%)	12.4%	(11.2%; 13.6%)	7.8%	(6.8%; 8.9%)	6.1%	(5.2%; 7.1%)	5.0%	(4.1%; 6.0%)	3.9%	(2.8%; 5.3%)
	X/NA	241	33.3%	(27.8%; 39.8%)	19.6%	(15.1%; 25.4%)	13.1%	(9.4%; 18.3%)	11.9%	(8.4%; 17.0%)	10.6%	(7.2%; 15.6%)	9.6%	(6.2%; 14.8%)
NSCLC	**All**	23,362	64.5%	(63.9%; 65.1%)	51.8%	(51.2%; 52.5%)	44.7%	(44.0%; 45.4%)	40.0%	(39.3%; 40.8%)	36.5%	(35.8%; 37.3%)	25.4%	(23.9%; 26.9%)
	I	5,550	95.1%	(94.5%; 95.8%)	89.0%	(88.0%; 90.0%)	84.0%	(82.8%; 85.2%)	79.4%	(78.0%; 80.8%)	74.9%	(73.3%; 76.6%)	53.6%	(47.8%; 60.1%)
	II	1,624	85.1%	(83.3%; 87.0%)	73.7%	(71.4%; 76.0%)	66.0%	(63.5%; 68.7%)	59.0%	(56.2%; 61.9%)	53.2%	(50.2%; 56.4%)	37.9%	(32.6%; 44.0%)
	III	3,995	69.7%	(68.2%; 71.2%)	52.6%	(51.0%; 54.2%)	43.5%	(41.9%; 45.2%)	38.0%	(36.3%; 39.7%)	34.1%	(32.4%; 35.9%)	21.2%	(18.8%; 23.8%)
	IV	11,009	44.8%	(43.9%; 45.8%)	29.9%	(29.0%; 30.7%)	22.4%	(21.5%; 23.2%)	18.0%	(17.2%; 18.8%)	15.3%	(14.5%; 16.1%)	8.9%	(7.8%; 10.1%)

Net Survival Probability, 2015-2024										
Type	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	X/NA	1,384	62.1% (59.5%; 64.7%)	52.8% (50.1%; 55.6%)	47.5% (44.8%; 50.4%)	45.0% (42.2%; 48.0%)	41.9% (39.0%; 44.9%)	33.7% (30.3%; 37.4%)
SCC	**All**	4,539	62.7% (61.2%; 64.1%)	47.2% (45.7%; 48.8%)	39.4% (37.9%; 41.0%)	35.2% (33.7%; 36.8%)	31.5% (29.9%; 33.1%)	18.2% (16.0%; 20.6%)
	I	1,103	91.5% (89.7%; 93.4%)	80.9% (78.4%; 83.6%)	72.8% (69.8%; 76.0%)	67.1% (63.8%; 70.6%)	60.5% (56.8%; 64.5%)	32.2% (25.7%; 40.2%)
	II	479	77.7% (73.9%; 81.7%)	61.4% (57.0%; 66.3%)	53.3% (48.6%; 58.5%)	47.3% (42.4%; 52.8%)	41.0% (35.9%; 46.9%)	28.9% (21.4%; 38.8%)
	III	1,289	59.8% (57.1%; 62.6%)	40.2% (37.5%; 43.1%)	30.8% (28.2%; 33.6%)	27.4% (24.8%; 30.2%)	24.4% (21.8%; 27.2%)	12.0% (9.0%; 16.1%)
	IV	1,392	36.9% (34.4%; 39.5%)	21.1% (19.0%; 23.5%)	15.3% (13.4%; 17.5%)	12.2% (10.5%; 14.3%)	10.4% (8.6%; 12.4%)	4.8% (2.8%; 8.1%)
	X/NA	276	64.6% (59.1%; 70.7%)	52.9% (47.1%; 59.4%)	44.8% (38.9%; 51.5%)	40.8% (34.8%; 47.7%)	38.7% (32.7%; 45.8%)	29.4% (22.7%; 38.1%)
ADC	**All**	17,607	66.7% (66.0%; 67.4%)	54.7% (53.9%; 55.4%)	47.5% (46.7%; 48.3%)	42.5% (41.7%; 43.4%)	38.9% (38.0%; 39.8%)	28.2% (26.3%; 30.1%)
	I	4,307	96.4% (95.8%; 97.1%)	91.7% (90.7%; 92.7%)	87.4% (86.1%; 88.7%)	83.1% (81.6%; 84.6%)	79.2% (77.4%; 81.0%)	59.5% (52.2%; 67.8%)
	II	1,066	88.9% (86.8%; 90.9%)	79.9% (77.3%; 82.7%)	72.4% (69.3%; 75.5%)	65.0% (61.6%; 68.6%)	58.8% (55.1%; 62.8%)	43.2% (37.5%; 49.8%)
	III	2,435	76.1% (74.3%; 77.9%)	60.3% (58.3%; 62.4%)	51.2% (49.1%; 53.4%)	44.1% (42.0%; 46.4%)	39.7% (37.5%; 42.1%)	26.9% (23.6%; 30.6%)
	IV	8,904	47.7% (46.6%; 48.8%)	32.4% (31.5%; 33.5%)	24.3% (23.4%; 25.3%)	19.5% (18.6%; 20.4%)	16.5% (15.7%; 17.5%)	9.5% (8.3%; 10.9%)
	X/NA	1,005	64.4% (61.4%; 67.5%)	55.7% (52.6%; 59.0%)	51.3% (48.1%; 54.7%)	49.3% (46.0%; 52.8%)	45.8% (42.4%; 49.4%)	37.6% (33.6%; 42.2%)
LCC	**All**	515	45.1% (40.9%; 49.6%)	32.0% (28.2%; 36.4%)	27.6% (23.9%; 32.0%)	24.6% (20.9%; 28.9%)	22.8% (19.1%; 27.3%)	14.9% (10.2%; 21.5%)
	I	92	87.1% (80.1%; 94.7%)	74.5% (65.5%; 84.7%)	70.6% (61.0%; 81.7%)	67.1% (56.9%; 79.2%)	64.0% (53.2%; 76.9%)	49.9% (32.2%; 77.5%)
	II	32	N<50	N<50	N<50	N<50	N<50	N<50
	III	76	58.4% (48.3%; 70.6%)	42.7% (32.8%; 55.5%)	32.8% (23.6%; 45.7%)	29.8% (20.8%; 42.7%)	26.0% (17.2%; 39.3%)	FU<10y
	IV	290	25.2% (20.6%; 30.7%)	12.4% (9.1%; 17.0%)	10.1% (7.1%; 14.4%)	8.2% (5.4%; 12.4%)	8.3% (5.5%; 12.6%)	FU<10y
	X/NA	25	N<50	N<50	N<50	N<50	N<50	N<50
Other NSCLC	**All**	864	44.1% (40.9%; 47.6%)	32.2% (29.2%; 35.6%)	27.8% (24.8%; 31.2%)	25.4% (22.4%; 28.9%)	23.3% (20.2%; 26.9%)	14.8% (10.0%; 21.8%)
	I	97	85.1% (78.0%; 93.0%)	72.5% (63.5%; 82.8%)	66.5% (56.7%; 78.0%)	57.9% (47.3%; 70.8%)	49.0% (37.5%; 64.1%)	31.3% (17.6%; 55.6%)
	II	53	80.3% (70.0%; 92.1%)	67.7% (55.8%; 82.2%)	64.4% (51.9%; 79.8%)	60.9% (47.8%; 77.6%)	62.6% (49.1%; 79.8%)	35.8% (14.0%; 91.2%)
	III	201	59.6% (53.0%; 66.9%)	41.4% (34.9%; 49.3%)	35.4% (28.9%; 43.5%)	34.4% (27.7%; 42.8%)	31.7% (24.7%; 40.8%)	19.7% (11.6%; 33.3%)
	IV	428	24.9% (21.1%; 29.4%)	16.2% (13.0%; 20.2%)	12.7% (9.7%; 16.4%)	11.7% (8.9%; 15.5%)	10.4% (7.6%; 14.1%)	9.8% (6.7%; 14.1%)

Net Survival Probability, 2015-2024												
Type	**cStage**	**N at risk**	**1-y**	**(95%CI)**	**2-y**	**(95%CI)**	**3-y**	**(95%CI)**	**4-y**	**(95%CI)**	**5-y**	**(95%CI)**	**10-y**	**(95%CI)**
	X/NA	85	34.6%	(25.8%; 46.4%)	22.9%	(15.4%; 33.9%)	18.3%	(11.7%; 28.8%)	14.5%	(8.6%; 24.5%)	14.5%	(8.6%; 24.5%)	10.0%	(4.6%; 21.6%)
Other	**All**	4,490	66.2%	(64.7%; 67.6%)	57.8%	(56.3%; 59.4%)	52.0%	(50.4%; 53.7%)	47.6%	(45.8%; 49.4%)	45.2%	(43.3%; 47.2%)	36.4%	(32.9%; 40.2%)
	I	2,270	90.1%	(88.7%; 91.5%)	82.0%	(80.2%; 83.9%)	75.3%	(73.1%; 77.5%)	68.5%	(66.0%; 71.2%)	64.9%	(62.0%; 68.0%)	49.5%	(43.8%; 56.0%)
	II	292	76.6%	(71.4%; 82.1%)	63.7%	(57.7%; 70.4%)	52.1%	(45.5%; 59.6%)	48.2%	(41.2%; 56.5%)	49.5%	(42.0%; 58.4%)	21.0%	(8.9%; 49.4%)
	III	431	43.6%	(39.0%; 48.8%)	30.1%	(25.7%; 35.2%)	22.7%	(18.6%; 27.7%)	21.2%	(17.0%; 26.3%)	17.8%	(13.7%; 23.1%)	11.5%	(7.3%; 18.0%)
	IV	1,120	21.2%	(18.9%; 23.8%)	15.1%	(13.1%; 17.5%)	12.9%	(10.8%; 15.3%)	12.0%	(9.9%; 14.4%)	11.1%	(9.0%; 13.6%)	9.1%	(6.3%; 13.1%)
	X/NA	383	72.8%	(68.2%; 77.7%)	65.5%	(60.5%; 71.0%)	61.7%	(56.3%; 67.6%)	56.5%	(50.5%; 63.3%)	55.4%	(49.1%; 62.6%)	60.0%	(49.3%; 72.9%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.2. Lung cancer survival by histological type, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Type	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All**	87,812	56.5% (56.1%; 56.8%)	42.8% (42.4%; 43.1%)	35.9% (35.5%; 36.2%)	31.5% (31.1%; 31.9%)	28.4% (28.0%; 28.7%)	18.6% (17.9%; 19.3%)
Males								
Lung	**All**	55,611	53.6% (53.1%; 54.0%)	39.5% (39.1%; 39.9%)	32.5% (32.1%; 33.0%)	28.2% (27.8%; 28.6%)	25.1% (24.6%; 25.5%)	15.5% (14.7%; 16.3%)
	I	6,146	96.1% (95.5%; 96.8%)	91.8% (90.9%; 92.7%)	87.4% (86.3%; 88.5%)	83.8% (82.5%; 85.2%)	79.8% (78.2%; 81.3%)	60.6% (57.2%; 64.2%)
	II	2,468	90.3% (89.0%; 91.7%)	80.7% (79.0%; 82.5%)	74.5% (72.5%; 76.6%)	68.9% (66.6%; 71.2%)	64.1% (61.7%; 66.7%)	46.8% (40.8%; 53.6%)
	III	1,622	78.0% (75.9%; 80.1%)	62.3% (59.8%; 64.9%)	52.0% (49.3%; 54.8%)	46.1% (43.4%; 49.1%)	42.8% (40.0%; 45.8%)	27.5% (23.3%; 32.6%)
	IV	3,830	32.8% (31.3%; 34.3%)	19.7% (18.5%; 21.1%)	14.9% (13.7%; 16.2%)	12.1% (11.0%; 13.3%)	10.3% (9.2%; 11.5%)	5.7% (4.4%; 7.4%)
	X/NA	42,000	46.3% (45.8%; 46.8%)	30.6% (30.1%; 31.1%)	23.1% (22.6%; 23.6%)	18.6% (18.1%; 19.0%)	15.5% (15.0%; 15.9%)	7.0% (6.3%; 7.8%)
SCLC	**All**	7,282	34.4% (33.3%; 35.6%)	15.9% (15.1%; 16.8%)	11.2% (10.5%; 12.0%)	9.0% (8.2%; 9.7%)	7.8% (7.1%; 8.6%)	4.5% (3.7%; 5.6%)
	I	94	88.1% (81.2%; 95.5%)	65.7% (56.2%; 76.9%)	57.8% (47.6%; 70.1%)	50.4% (39.7%; 63.9%)	46.7% (35.4%; 61.7%)	34.7% (20.5%; 58.7%)
	II	54	81.3% (71.1%; 93.0%)	61.5% (49.2%; 76.9%)	53.7% (41.0%; 70.4%)	50.7% (37.7%; 68.3%)	44.0% (31.0%; 62.7%)	27.0% (15.0%; 48.6%)
	III	62	51.2% (40.0%; 65.5%)	26.8% (17.7%; 40.6%)	20.4% (12.4%; 33.7%)	18.7% (10.9%; 32.1%)	14.9% (8.0%; 27.7%)	11.3% (5.3%; 24.4%)
	IV	628	20.3% (17.3%; 23.7%)	6.6% (4.9%; 8.9%)	3.5% (2.2%; 5.5%)	3.0% (1.8%; 4.9%)	2.4% (1.3%; 4.5%)	1.4% (0.6%; 3.7%)
	X/NA	6,444	34.5% (33.3%; 35.7%)	15.6% (14.7%; 16.6%)	10.8% (10.0%; 11.7%)	8.5% (7.7%; 9.3%)	7.4% (6.7%; 8.2%)	4.2% (3.3%; 5.3%)
NSCLC	**All**	41,921	56.9% (56.4%; 57.4%)	43.2% (42.7%; 43.7%)	35.8% (35.3%; 36.3%)	31.2% (30.7%; 31.7%)	27.9% (27.4%; 28.4%)	17.7% (16.8%; 18.6%)
	I	5,801	96.1% (95.4%; 96.7%)	91.8% (90.9%; 92.8%)	87.4% (86.2%; 88.6%)	83.7% (82.3%; 85.1%)	79.5% (77.9%; 81.1%)	60.2% (56.8%; 63.9%)
	II	2,357	90.3% (89.0%; 91.7%)	80.7% (78.9%; 82.5%)	74.4% (72.4%; 76.6%)	68.7% (66.4%; 71.1%)	63.9% (61.4%; 66.6%)	46.6% (40.5%; 53.7%)
	III	1,526	79.0% (76.9%; 81.2%)	63.5% (61.0%; 66.2%)	52.9% (50.2%; 55.8%)	47.0% (44.2%; 50.0%)	43.6% (40.7%; 46.8%)	27.7% (23.2%; 32.9%)
	IV	3,095	35.5% (33.8%; 37.2%)	22.5% (21.0%; 24.1%)	17.3% (15.9%; 18.8%)	13.9% (12.6%; 15.4%)	11.9% (10.6%; 13.4%)	6.4% (4.8%; 8.4%)
	X/NA	29,410	47.7% (47.1%; 48.3%)	31.9% (31.4%; 32.5%)	23.8% (23.3%; 24.4%)	19.0% (18.5%; 19.6%)	15.8% (15.2%; 16.3%)	7.3% (6.5%; 8.1%)
SCC	**All**	15,135	59.4% (58.6%; 60.2%)	43.8% (42.9%; 44.6%)	35.3% (34.5%; 36.2%)	30.2% (29.4%; 31.1%)	26.4% (25.6%; 27.3%)	16.1% (14.8%; 17.5%)
	I	1,861	94.5% (93.2%; 95.8%)	89.1% (87.4%; 90.9%)	83.5% (81.4%; 85.8%)	78.7% (76.2%; 81.3%)	72.8% (69.9%; 75.7%)	52.1% (46.7%; 58.1%)

Net Survival Probability, 2015-2024								
Type	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	II	999	91.4% (89.5%; 93.4%)	81.7% (78.9%; 84.5%)	75.7% (72.6%; 79.0%)	69.9% (66.4%; 73.6%)	64.2% (60.4%; 68.4%)	49.8% (42.8%; 57.9%)
	III	594	78.1% (74.7%; 81.8%)	61.8% (57.7%; 66.1%)	51.8% (47.5%; 56.5%)	45.9% (41.4%; 50.9%)	43.3% (38.6%; 48.5%)	29.7% (22.4%; 39.3%)
	IV	474	34.6% (30.5%; 39.3%)	19.2% (15.8%; 23.3%)	14.5% (11.5%; 18.4%)	12.4% (9.5%; 16.2%)	9.7% (7.0%; 13.3%)	8.5% (5.6%; 13.0%)
	X/NA	11,214	50.8% (49.9%; 51.8%)	32.9% (32.0%; 33.9%)	23.7% (22.9%; 24.6%)	18.5% (17.6%; 19.3%)	15.0% (14.2%; 15.9%)	6.2% (5.1%; 7.5%)
ADC	**All**	24,077	57.5% (56.9%; 58.2%)	44.9% (44.2%; 45.6%)	37.9% (37.2%; 38.6%)	33.4% (32.7%; 34.1%)	30.1% (29.4%; 30.8%)	19.5% (18.3%; 20.9%)
	I	3,751	97.3% (96.5%; 98.0%)	94.1% (93.1%; 95.2%)	90.2% (88.8%; 91.5%)	87.0% (85.4%; 88.7%)	83.4% (81.5%; 85.3%)	65.2% (60.8%; 70.0%)
	II	1,257	90.6% (88.8%; 92.4%)	80.9% (78.4%; 83.4%)	74.6% (71.8%; 77.5%)	69.0% (65.9%; 72.3%)	64.5% (61.1%; 68.1%)	44.5% (35.3%; 56.0%)
	III	846	81.5% (78.8%; 84.3%)	66.5% (63.2%; 70.0%)	54.7% (51.1%; 58.5%)	48.5% (44.7%; 52.6%)	44.4% (40.5%; 48.6%)	25.7% (20.3%; 32.5%)
	IV	2,286	37.2% (35.2%; 39.3%)	24.0% (22.2%; 25.9%)	18.5% (16.8%; 20.3%)	14.9% (13.3%; 16.6%)	12.8% (11.3%; 14.6%)	6.4% (4.6%; 9.1%)
	X/NA	16,043	47.5% (46.7%; 48.3%)	32.7% (31.9%; 33.4%)	24.9% (24.2%; 25.6%)	20.1% (19.4%; 20.9%)	16.8% (16.0%; 17.5%)	8.1% (7.1%; 9.3%)
LCC	**All**	1,146	40.3% (37.5%; 43.3%)	28.2% (25.6%; 31.1%)	23.4% (20.9%; 26.2%)	20.5% (18.0%; 23.4%)	19.9% (17.3%; 22.9%)	10.3% (6.8%; 15.6%)
	I	123	91.3% (85.9%; 97.1%)	73.8% (65.8%; 82.9%)	70.3% (61.7%; 80.2%)	67.3% (58.0%; 78.1%)	68.6% (59.1%; 79.6%)	43.9% (28.6%; 67.3%)
	II	55	79.8% (69.5%; 91.6%)	69.9% (58.1%; 84.0%)	58.4% (45.7%; 74.5%)	50.3% (37.1%; 68.0%)	51.4% (38.0%; 69.6%)	31.6% (13.7%; 73.0%)
	III	38	N<50	N<50	N<50	N<50	N<50	N<50
	IV	152	23.1% (17.2%; 31.0%)	12.8% (8.3%; 19.6%)	9.4% (5.6%; 15.7%)	5.2% (2.5%; 10.8%)	5.3% (2.5%; 11.0%)	3.8% (1.4%; 10.3%)
	X/NA	778	31.3% (28.1%; 34.8%)	19.6% (16.8%; 22.7%)	14.7% (12.2%; 17.7%)	12.7% (10.3%; 15.7%)	11.2% (8.8%; 14.3%)	FU<10y
Other NSCLC	**All**	1,910	40.4% (38.2%; 42.7%)	28.6% (26.5%; 30.8%)	23.3% (21.3%; 25.5%)	20.2% (18.2%; 22.5%)	18.2% (16.1%; 20.5%)	12.0% (9.4%; 15.4%)
	I	123	90.6% (85.1%; 96.5%)	81.4% (73.8%; 89.8%)	79.9% (71.6%; 89.2%)	76.2% (66.8%; 87.0%)	69.5% (58.7%; 82.4%)	39.4% (22.5%; 69.2%)
	II	53	71.5% (60.0%; 85.2%)	68.7% (56.7%; 83.2%)	60.1% (47.3%; 76.4%)	56.6% (43.3%; 74.0%)	58.2% (44.5%; 76.0%)	47.8% (27.4%; 83.5%)
	III	48	N<50	N<50	N<50	N<50	N<50	N<50
	IV	184	26.1% (20.4%; 33.3%)	20.3% (15.1%; 27.3%)	15.7% (10.9%; 22.5%)	13.6% (9.1%; 20.4%)	12.1% (7.6%; 19.2%)	2.2% (0.5%; 9.4%)
	X/NA	1,502	36.5% (34.1%; 39.1%)	23.7% (21.5%; 26.0%)	18.1% (16.0%; 20.4%)	14.9% (12.9%; 17.2%)	13.1% (11.1%; 15.4%)	8.9% (6.4%; 12.4%)
Other	**All**	6,821	54.3% (53.0%; 55.5%)	42.3% (41.0%; 43.7%)	35.4% (34.1%; 36.8%)	30.3% (28.9%; 31.8%)	26.0% (24.5%; 27.6%)	12.5% (9.6%; 16.2%)
	I	262	100.3% (99.0%; 101.6%)	100.5% (98.3%; 102.7%)	98.2% (94.7%; 101.8%)	98.9% (94.9%; 103.1%)	98.2% (93.4%; 103.2%)	79.2% (61.9%; 101.5%)

Type	pStage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	II	60	95.9% (90.4%; 101.6%)	94.3% (86.5%; 102.7%)	93.5% (84.6%; 103.4%)	89.1% (78.4%; 101.3%)	88.0% (76.2%; 101.6%)	76.6% (58.7%; 99.9%)
	III	34	N<50	N<50	N<50	N<50	N<50	N<50
	IV	108	28.7% (21.2%; 38.7%)	18.6% (12.4%; 27.9%)	14.4% (8.8%; 23.4%)	13.0% (7.5%; 22.5%)	10.8% (5.5%; 20.9%)	13.2% (6.8%; 25.7%)
	X/NA	6,358	52.3% (51.0%; 53.6%)	39.7% (38.4%; 41.1%)	32.5% (31.1%; 33.9%)	27.1% (25.6%; 28.6%)	22.4% (20.9%; 24.1%)	8.1% (5.5%; 12.0%)
Females								
Lung	**All**	32,201	61.5% (61.0%; 62.1%)	48.5% (47.9%; 49.1%)	41.7% (41.1%; 42.3%)	37.2% (36.6%; 37.8%)	34.1% (33.5%; 34.8%)	24.3% (23.2%; 25.5%)
	I	4,798	98.5% (98.0%; 98.9%)	96.2% (95.5%; 96.9%)	93.7% (92.8%; 94.6%)	91.2% (90.0%; 92.4%)	88.6% (87.3%; 90.0%)	76.6% (73.4%; 80.0%)
	II	1,370	93.2% (91.7%; 94.7%)	86.6% (84.6%; 88.6%)	82.3% (80.0%; 84.7%)	76.1% (73.4%; 78.9%)	71.5% (68.5%; 74.6%)	57.4% (51.9%; 63.4%)
	III	946	87.8% (85.7%; 90.1%)	76.1% (73.3%; 79.1%)	66.6% (63.3%; 69.9%)	58.2% (54.7%; 61.9%)	54.0% (50.4%; 58.0%)	39.8% (34.4%; 46.1%)
	IV	2,286	41.9% (39.8%; 44.0%)	28.0% (26.1%; 30.0%)	21.0% (19.2%; 22.8%)	17.4% (15.8%; 19.3%)	15.0% (13.3%; 16.8%)	9.5% (7.7%; 11.8%)
	X/NA	23,119	53.1% (52.5%; 53.8%)	37.5% (36.9%; 38.2%)	29.8% (29.1%; 30.4%)	25.1% (24.5%; 25.8%)	21.9% (21.2%; 22.6%)	12.2% (10.8%; 13.6%)
SCLC	**All**	4,656	42.7% (41.3%; 44.1%)	23.2% (22.0%; 24.5%)	16.8% (15.7%; 18.0%)	13.7% (12.6%; 14.8%)	11.9% (10.9%; 13.0%)	7.7% (6.4%; 9.2%)
	I	67	94.9% (89.4%; 100.8%)	85.1% (76.4%; 94.8%)	70.6% (59.6%; 83.7%)	65.2% (53.4%; 79.6%)	58.1% (45.4%; 74.3%)	47.9% (32.9%; 69.8%)
	II	35	N<50	N<50	N<50	N<50	N<50	N<50
	III	33	N<50	N<50	N<50	N<50	N<50	N<50
	IV	363	28.1% (23.8%; 33.2%)	11.7% (8.8%; 15.7%)	6.9% (4.7%; 10.3%)	5.0% (3.1%; 8.0%)	3.9% (2.3%; 6.8%)	3.2% (1.5%; 6.6%)
	X/NA	4,158	42.5% (41.0%; 44.1%)	22.6% (21.3%; 23.9%)	16.3% (15.2%; 17.6%)	13.3% (12.2%; 14.5%)	11.6% (10.5%; 12.8%)	7.1% (5.8%; 8.7%)
NSCLC	**All**	23,362	64.5% (63.9%; 65.1%)	51.8% (51.2%; 52.5%)	44.7% (44.0%; 45.4%)	40.0% (39.3%; 40.8%)	36.5% (35.8%; 37.3%)	25.4% (23.9%; 26.9%)
	I	4,162	98.2% (97.7%; 98.8%)	95.8% (95.0%; 96.6%)	93.2% (92.1%; 94.2%)	90.3% (89.1%; 91.6%)	87.2% (85.7%; 88.8%)	72.6% (69.1%; 76.3%)
	II	1,245	93.1% (91.6%; 94.7%)	86.2% (84.1%; 88.3%)	81.6% (79.2%; 84.1%)	75.3% (72.5%; 78.3%)	70.3% (67.2%; 73.6%)	55.8% (50.2%; 62.0%)
	III	860	87.9% (85.7%; 90.2%)	76.6% (73.6%; 79.6%)	66.6% (63.3%; 70.2%)	58.2% (54.6%; 62.1%)	53.8% (49.9%; 57.9%)	39.0% (33.3%; 45.7%)
	IV	1,845	44.6% (42.3%; 46.9%)	30.9% (28.8%; 33.2%)	23.5% (21.5%; 25.6%)	19.6% (17.7%; 21.7%)	16.7% (14.8%; 18.9%)	9.9% (7.8%; 12.6%)
	X/NA	15,425	54.4% (53.6%; 55.2%)	38.6% (37.8%; 39.4%)	30.3% (29.5%; 31.1%)	25.3% (24.6%; 26.1%)	21.8% (21.0%; 22.6%)	11.0% (9.2%; 13.0%)
SCC	**All**	4,539	62.7% (61.2%; 64.1%)	47.2% (45.7%; 48.8%)	39.4% (37.9%; 41.0%)	35.2% (33.7%; 36.8%)	31.5% (29.9%; 33.1%)	18.2% (16.0%; 20.6%)

Type	pStage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	I	689	96.6% (95.0%; 98.2%)	91.8% (89.4%; 94.2%)	87.4% (84.4%; 90.5%)	82.2% (78.5%; 86.0%)	77.9% (73.8%; 82.3%)	57.3% (49.4%; 66.5%)
	II	274	89.9% (86.2%; 93.8%)	80.9% (76.0%; 86.1%)	76.7% (71.2%; 82.5%)	68.8% (62.7%; 75.6%)	62.3% (55.5%; 69.9%)	42.1% (30.7%; 57.6%)
	III	152	81.4% (75.3%; 88.1%)	60.8% (53.2%; 69.4%)	49.2% (41.4%; 58.4%)	46.5% (38.6%; 56.0%)	44.6% (36.5%; 54.5%)	25.1% (13.6%; 46.3%)
	IV	145	37.7% (30.5%; 46.5%)	21.6% (15.7%; 29.7%)	19.3% (13.6%; 27.3%)	17.3% (11.9%; 25.4%)	12.3% (7.3%; 20.6%)	3.0% (0.8%; 11.3%)
	X/NA	3,279	53.5% (51.8%; 55.3%)	35.6% (33.9%; 37.3%)	26.7% (25.1%; 28.4%)	22.8% (21.2%; 24.5%)	19.3% (17.8%; 21.0%)	8.1% (6.2%; 10.4%)
ADC	**All**	17,607	66.7% (66.0%; 67.4%)	54.7% (53.9%; 55.4%)	47.5% (46.7%; 48.3%)	42.5% (41.7%; 43.4%)	38.9% (38.0%; 39.8%)	28.2% (26.3%; 30.1%)
	I	3,388	98.7% (98.2%; 99.3%)	96.9% (96.1%; 97.7%)	94.7% (93.6%; 95.8%)	92.4% (91.1%; 93.7%)	89.5% (87.9%; 91.2%)	76.1% (72.2%; 80.2%)
	II	910	94.9% (93.4%; 96.6%)	88.8% (86.5%; 91.1%)	84.5% (81.8%; 87.3%)	78.5% (75.3%; 81.9%)	73.6% (70.0%; 77.4%)	61.3% (55.3%; 67.9%)
	III	659	90.2% (87.9%; 92.7%)	81.3% (78.1%; 84.5%)	71.1% (67.4%; 75.1%)	60.5% (56.3%; 65.0%)	55.0% (50.6%; 59.8%)	42.1% (36.3%; 48.9%)
	IV	1,550	47.0% (44.5%; 49.6%)	33.2% (30.8%; 35.7%)	24.7% (22.5%; 27.1%)	20.4% (18.2%; 22.8%)	17.5% (15.4%; 20.0%)	11.5% (9.3%; 14.2%)
	X/NA	11,203	56.3% (55.4%; 57.2%)	40.8% (39.8%; 41.7%)	32.3% (31.4%; 33.3%)	26.8% (25.9%; 27.8%)	23.1% (22.1%; 24.0%)	12.2% (10.0%; 15.0%)
LCC	**All**	515	45.1% (40.9%; 49.6%)	32.0% (28.2%; 36.4%)	27.6% (23.9%; 32.0%)	24.6% (20.9%; 28.9%)	22.8% (19.1%; 27.3%)	14.9% (10.2%; 21.5%)
	I	63	93.1% (86.5%; 100.1%)	84.2% (75.1%; 94.5%)	80.0% (69.8%; 91.6%)	75.3% (64.0%; 88.6%)	68.6% (56.1%; 83.9%)	57.9% (35.2%; 95.4%)
	II	35	N<50	N<50	N<50	N<50	N<50	N<50
	III	21	N<50	N<50	N<50	N<50	N<50	N<50
	IV	72	23.9% (15.9%; 36.0%)	8.5% (4.1%; 17.7%)	8.5% (4.1%; 17.8%)	5.8% (2.2%; 15.4%)	5.8% (2.2%; 15.6%)	FU<10y
	X/NA	324	34.1% (29.3%; 39.7%)	21.1% (17.0%; 26.2%)	16.4% (12.7%; 21.2%)	13.3% (9.8%; 17.9%)	11.8% (8.5%; 16.5%)	3.4% (1.1%; 10.3%)
Other NSCLC	**All**	864	44.1% (40.9%; 47.6%)	32.2% (29.2%; 35.6%)	27.8% (24.8%; 31.2%)	25.4% (22.4%; 28.9%)	23.3% (20.2%; 26.9%)	14.8% (10.0%; 21.8%)
	I	56	92.4% (85.2%; 100.3%)	88.4% (79.5%; 98.4%)	83.2% (72.4%; 95.5%)	74.7% (61.6%; 90.6%)	76.3% (62.9%; 92.6%)	57.8% (37.1%; 90.0%)
	II	27	N<50	N<50	N<50	N<50	N<50	N<50
	III	29	N<50	N<50	N<50	N<50	N<50	N<50
	IV	78	28.4% (20.1%; 40.3%)	24.6% (16.7%; 36.3%)	21.5% (14.0%; 33.2%)	21.7% (14.1%; 33.4%)	19.8% (12.3%; 31.7%)	6.9% (2.0%; 23.6%)
	X/NA	674	39.5% (36.0%; 43.5%)	25.7% (22.5%; 29.4%)	21.1% (18.0%; 24.6%)	18.9% (15.9%; 22.4%)	16.1% (13.1%; 19.8%)	9.8% (5.3%; 18.1%)
Other	**All**	4,490	66.2% (64.7%; 67.6%)	57.8% (56.3%; 59.4%)	52.0% (50.4%; 53.7%)	47.6% (45.8%; 49.4%)	45.2% (43.3%; 47.2%)	36.4% (32.9%; 40.2%)

Net Survival Probability, 2015-2024										
Type	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	I	589	100.5% (99.8%; 101.1%)	100.3% (99.1%; 101.5%)	100.2% (98.5%; 101.9%)	100.2% (98.1%; 102.4%)	102.1% (99.9%; 104.3%)	107.9% (101.6%; 114.5%)
	II	93	99.0% (97.0%; 101.1%)	97.9% (93.6%; 102.4%)	98.0% (92.8%; 103.4%)	96.1% (89.4%; 103.4%)	97.6% (90.8%; 105.0%)	83.7% (62.9%; 111.5%)
	III	53	93.3% (86.5%; 100.7%)	86.8% (77.6%; 97.1%)	87.7% (78.4%; 98.2%)	86.0% (75.7%; 97.7%)	84.2% (73.0%; 97.0%)	73.9% (54.4%; 100.5%)
	IV	78	41.7% (32.0%; 54.2%)	34.3% (25.1%; 46.9%)	27.8% (19.2%; 40.4%)	25.0% (16.5%; 37.8%)	25.0% (16.5%; 37.8%)	23.8% (13.9%; 40.9%)
	X/NA	3,678	59.9% (58.3%; 61.6%)	50.1% (48.3%; 51.9%)	43.1% (41.2%; 45.0%)	37.7% (35.7%; 39.7%)	34.3% (32.2%; 36.6%)	22.5% (18.8%; 26.9%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation. Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.3. Lung cancer survival by histological type, stage and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All**	87,812	56.5% (56.1%; 56.8%)	42.8% (42.4%; 43.1%)	35.9% (35.5%; 36.2%)	31.5% (31.1%; 31.9%)	28.4% (28.0%; 28.7%)	18.6% (17.9%; 19.3%)
Males								
Lung	**All**	55,611	53.6% (53.1%; 54.0%)	39.5% (39.1%; 39.9%)	32.5% (32.1%; 33.0%)	28.2% (27.8%; 28.6%)	25.1% (24.6%; 25.5%)	15.5% (14.7%; 16.3%)
	I	11,276	90.5% (89.9%; 91.1%)	80.5% (79.6%; 81.4%)	72.9% (71.9%; 73.9%)	66.2% (65.1%; 67.4%)	60.3% (59.0%; 61.6%)	39.1% (36.6%; 41.8%)
	II	4,480	80.5% (79.3%; 81.8%)	65.6% (64.0%; 67.2%)	56.3% (54.6%; 58.0%)	50.0% (48.2%; 51.9%)	45.4% (43.5%; 47.4%)	30.5% (26.6%; 35.0%)
	III	11,274	62.0% (61.1%; 63.0%)	43.1% (42.1%; 44.1%)	33.3% (32.3%; 34.2%)	27.8% (26.9%; 28.8%)	24.6% (23.6%; 25.6%)	14.3% (13.0%; 15.8%)
	IV	26,594	31.7% (31.1%; 32.3%)	17.8% (17.4%; 18.3%)	12.6% (12.1%; 13.0%)	10.0% (9.5%; 10.4%)	8.2% (7.8%; 8.6%)	4.4% (3.9%; 5.0%)
	X/NA	2,577	36.1% (34.2%; 38.1%)	24.3% (22.6%; 26.2%)	19.7% (18.0%; 21.4%)	15.5% (14.0%; 17.3%)	13.0% (11.4%; 14.7%)	5.3% (3.3%; 8.7%)
SCLC	**All**	7,282	34.4% (33.3%; 35.6%)	15.9% (15.1%; 16.8%)	11.2% (10.5%; 12.0%)	9.0% (8.2%; 9.7%)	7.8% (7.1%; 8.6%)	4.5% (3.7%; 5.6%)
	I	255	83.1% (78.2%; 88.3%)	56.2% (50.0%; 63.3%)	44.8% (38.4%; 52.4%)	36.0% (29.5%; 43.9%)	32.0% (25.2%; 40.5%)	13.4% (6.9%; 25.9%)
	II	226	78.2% (72.6%; 84.1%)	51.0% (44.5%; 58.5%)	43.8% (37.2%; 51.6%)	38.1% (31.4%; 46.1%)	32.1% (25.5%; 40.3%)	19.3% (10.6%; 35.0%)
	III	1,477	57.5% (54.9%; 60.1%)	32.0% (29.6%; 34.6%)	24.0% (21.8%; 26.5%)	18.9% (16.7%; 21.2%)	17.2% (15.1%; 19.6%)	10.8% (8.3%; 14.0%)
	IV	4,913	24.1% (23.0%; 25.4%)	8.0% (7.3%; 8.9%)	4.6% (4.0%; 5.3%)	3.6% (3.1%; 4.3%)	3.0% (2.4%; 3.7%)	1.7% (1.1%; 2.8%)
	X/NA	411	20.3% (16.7%; 24.7%)	7.8% (5.5%; 11.0%)	5.0% (3.2%; 7.7%)	4.0% (2.4%; 6.7%)	3.1% (1.7%; 5.7%)	1.6% (0.6%; 4.0%)
NSCLC	**All**	41,921	56.9% (56.4%; 57.4%)	43.2% (42.7%; 43.7%)	35.8% (35.3%; 36.3%)	31.2% (30.7%; 31.7%)	27.9% (27.4%; 28.4%)	17.7% (16.8%; 18.6%)
	I	8,302	92.0% (91.3%; 92.7%)	83.7% (82.8%; 84.7%)	76.8% (75.7%; 78.0%)	70.8% (69.5%; 72.1%)	65.1% (63.6%; 66.6%)	45.0% (42.2%; 47.9%)
	II	3,741	82.3% (80.9%; 83.6%)	68.5% (66.9%; 70.2%)	59.4% (57.6%; 61.3%)	53.1% (51.2%; 55.2%)	48.7% (46.6%; 50.8%)	32.5% (28.1%; 37.6%)
	III	8,915	65.1% (64.0%; 66.1%)	46.8% (45.7%; 47.9%)	36.4% (35.3%; 37.5%)	30.7% (29.6%; 31.9%)	27.1% (26.0%; 28.3%)	15.4% (13.8%; 17.2%)
	IV	19,570	35.5% (34.8%; 36.2%)	21.4% (20.8%; 22.0%)	15.4% (14.8%; 15.9%)	12.1% (11.6%; 12.7%)	10.1% (9.6%; 10.6%)	5.4% (4.7%; 6.2%)
	X/NA	1,708	35.2% (32.9%; 37.6%)	23.8% (21.8%; 26.1%)	18.5% (16.5%; 20.6%)	14.0% (12.2%; 16.0%)	11.1% (9.5%; 13.1%)	4.1% (2.7%; 6.4%)
SCC	**All**	15,135	59.4% (58.6%; 60.2%)	43.8% (42.9%; 44.6%)	35.3% (34.5%; 36.2%)	30.2% (29.4%; 31.1%)	26.4% (25.6%; 27.3%)	16.1% (14.8%; 17.5%)
	I	3,087	88.8% (87.5%; 90.1%)	77.8% (76.0%; 79.5%)	69.6% (67.6%; 71.6%)	62.1% (59.9%; 64.4%)	54.6% (52.2%; 57.1%)	34.4% (30.5%; 38.9%)

Net Survival Probability, 2015-2024										
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	II	1,859	81.0% (79.1%; 83.0%)	66.0% (63.6%; 68.5%)	55.0% (52.4%; 57.7%)	48.8% (46.1%; 51.6%)	44.0% (41.1%; 47.0%)	31.6% (27.2%; 36.7%)
	III	4,560	61.9% (60.4%; 63.4%)	42.7% (41.1%; 44.2%)	31.7% (30.2%; 33.2%)	26.1% (24.7%; 27.7%)	23.1% (21.6%; 24.7%)	12.3% (10.2%; 14.7%)
	IV	4,924	34.2% (32.8%; 35.5%)	18.0% (17.0%; 19.2%)	12.2% (11.2%; 13.3%)	9.2% (8.3%; 10.2%)	7.3% (6.4%; 8.3%)	3.7% (2.6%; 5.4%)
	X/NA	713	34.9% (31.5%; 38.7%)	23.4% (20.3%; 26.9%)	18.5% (15.6%; 21.9%)	14.3% (11.6%; 17.6%)	11.4% (8.9%; 14.7%)	2.7% (1.0%; 7.1%)
ADC	**All**	24,077	57.5% (56.9%; 58.2%)	44.9% (44.2%; 45.6%)	37.9% (37.2%; 38.6%)	33.4% (32.7%; 34.1%)	30.1% (29.4%; 30.8%)	19.5% (18.3%; 20.9%)
	I	4,927	94.6% (93.8%; 95.4%)	88.7% (87.6%; 89.9%)	82.5% (81.1%; 83.9%)	77.6% (76.0%; 79.3%)	72.7% (70.8%; 74.6%)	53.1% (49.2%; 57.2%)
	II	1,688	85.2% (83.4%; 87.1%)	72.9% (70.5%; 75.3%)	65.9% (63.3%; 68.6%)	59.3% (56.5%; 62.3%)	54.7% (51.7%; 58.0%)	34.4% (26.8%; 44.0%)
	III	3,777	70.7% (69.2%; 72.3%)	53.3% (51.6%; 55.0%)	43.0% (41.3%; 44.8%)	36.7% (34.9%; 38.5%)	32.2% (30.4%; 34.1%)	19.0% (16.5%; 21.9%)
	IV	12,990	37.5% (36.6%; 38.3%)	23.7% (22.9%; 24.4%)	17.2% (16.5%; 17.9%)	13.8% (13.1%; 14.5%)	11.6% (10.9%; 12.2%)	6.1% (5.2%; 7.1%)
	X/NA	791	37.2% (33.9%; 40.8%)	25.3% (22.3%; 28.7%)	19.2% (16.5%; 22.5%)	14.3% (11.8%; 17.5%)	11.3% (8.9%; 14.3%)	5.1% (3.0%; 8.5%)
LCC	**All**	1,146	40.3% (37.5%; 43.3%)	28.2% (25.6%; 31.1%)	23.4% (20.9%; 26.2%)	20.5% (18.0%; 23.4%)	19.9% (17.3%; 22.9%)	10.3% (6.8%; 15.6%)
	I	147	89.4% (84.0%; 95.2%)	74.1% (66.5%; 82.5%)	67.3% (59.0%; 76.9%)	64.2% (55.1%; 74.9%)	61.5% (51.7%; 73.2%)	34.7% (21.6%; 55.7%)
	II	78	72.4% (62.8%; 83.5%)	63.2% (52.8%; 75.7%)	52.9% (42.0%; 66.7%)	46.5% (35.2%; 61.3%)	45.6% (33.9%; 61.3%)	23.9% (9.3%; 61.5%)
	III	217	53.0% (46.6%; 60.3%)	38.0% (31.8%; 45.4%)	32.2% (26.1%; 39.7%)	30.6% (24.4%; 38.3%)	29.2% (22.8%; 37.3%)	FU<10y
	IV	664	22.8% (19.8%; 26.3%)	11.7% (9.4%; 14.6%)	8.4% (6.4%; 11.0%)	5.3% (3.6%; 7.7%)	5.4% (3.7%; 7.8%)	4.7% (2.9%; 7.6%)
	X/NA	40	N<50	N<50	N<50	N<50	N<50	N<50
Other NSCLC	**All**	1,910	40.4% (38.2%; 42.7%)	28.6% (26.5%; 30.8%)	23.3% (21.3%; 25.5%)	20.2% (18.2%; 22.5%)	18.2% (16.1%; 20.5%)	12.0% (9.4%; 15.4%)
	I	230	82.3% (77.0%; 88.0%)	65.4% (58.8%; 72.8%)	60.0% (52.8%; 68.3%)	49.9% (42.0%; 59.1%)	45.7% (37.2%; 56.1%)	24.3% (14.4%; 41.1%)
	II	126	65.3% (57.0%; 74.7%)	49.3% (40.6%; 59.8%)	41.5% (32.6%; 52.7%)	39.6% (30.5%; 51.3%)	40.9% (31.5%; 53.0%)	26.1% (12.0%; 56.8%)
	III	380	52.7% (47.8%; 58.2%)	37.8% (33.0%; 43.3%)	29.4% (24.8%; 34.9%)	27.2% (22.6%; 32.7%)	23.8% (19.2%; 29.5%)	18.5% (12.9%; 26.4%)
	IV	1,010	24.7% (22.1%; 27.5%)	15.2% (13.0%; 17.7%)	11.3% (9.3%; 13.6%)	9.7% (7.7%; 12.0%)	8.4% (6.5%; 10.8%)	6.1% (3.8%; 9.7%)
	X/NA	165	30.8% (24.4%; 38.9%)	21.8% (16.1%; 29.5%)	17.6% (12.3%; 25.1%)	12.4% (7.9%; 19.6%)	9.7% (5.6%; 16.9%)	4.6% (1.7%; 12.0%)
Other	**All**	6,821	54.3% (53.0%; 55.5%)	42.3% (41.0%; 43.7%)	35.4% (34.1%; 36.8%)	30.3% (28.9%; 31.8%)	26.0% (24.5%; 27.6%)	12.5% (9.6%; 16.2%)
	I	2,818	86.9% (85.4%; 88.4%)	73.3% (71.3%; 75.3%)	63.4% (61.1%; 65.8%)	55.0% (52.4%; 57.7%)	47.9% (45.0%; 51.0%)	19.8% (14.5%; 27.0%)

Type	Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	II	521	68.4% (64.1%; 73.0%)	50.3% (45.5%; 55.5%)	38.1% (33.2%; 43.8%)	31.7% (26.6%; 37.8%)	27.1% (21.7%; 33.9%)	22.4% (15.3%; 32.8%)
	III	896	39.3% (36.1%; 42.9%)	24.4% (21.5%; 27.8%)	17.2% (14.5%; 20.3%)	13.8% (11.2%; 16.9%)	11.2% (8.6%; 14.6%)	10.5% (7.4%; 15.0%)
	IV	2,133	14.2% (12.8%; 15.8%)	7.4% (6.3%; 8.7%)	5.2% (4.3%; 6.5%)	4.4% (3.4%; 5.7%)	2.9% (2.0%; 4.1%)	1.2% (0.5%; 3.0%)
	X/NA	460	53.3% (48.6%; 58.4%)	40.7% (36.0%; 45.9%)	37.1% (32.2%; 42.6%)	31.5% (26.6%; 37.4%)	28.4% (23.2%; 34.7%)	14.7% (6.2%; 34.6%)
Females								
Lung	**All**	32,201	61.5% (61.0%; 62.1%)	48.5% (47.9%; 49.1%)	41.7% (41.1%; 42.3%)	37.2% (36.6%; 37.8%)	34.1% (33.5%; 34.8%)	24.3% (23.2%; 25.5%)
	I	7,888	93.8% (93.2%; 94.4%)	87.2% (86.3%; 88.1%)	81.6% (80.6%; 82.7%)	76.8% (75.6%; 78.0%)	72.8% (71.4%; 74.2%)	56.3% (52.5%; 60.3%)
	II	2,331	85.2% (83.7%; 86.8%)	73.7% (71.8%; 75.7%)	66.5% (64.4%; 68.8%)	59.9% (57.5%; 62.3%)	55.0% (52.5%; 57.6%)	38.6% (34.0%; 43.9%)
	III	5,813	67.7% (66.5%; 69.0%)	49.7% (48.4%; 51.0%)	40.4% (39.0%; 41.8%)	35.1% (33.8%; 36.5%)	31.4% (30.0%; 32.8%)	19.4% (17.6%; 21.5%)
	IV	15,218	40.3% (39.5%; 41.1%)	25.5% (24.8%; 26.2%)	19.0% (18.3%; 19.6%)	15.4% (14.7%; 16.0%)	13.2% (12.5%; 13.8%)	7.9% (7.1%; 8.9%)
	X/NA	1,334	47.7% (45.1%; 50.6%)	35.3% (32.7%; 38.1%)	29.9% (27.4%; 32.7%)	26.4% (23.8%; 29.2%)	24.4% (21.8%; 27.4%)	18.6% (15.0%; 23.0%)
SCLC	**All**	4,656	42.7% (41.3%; 44.1%)	23.2% (22.0%; 24.5%)	16.8% (15.7%; 18.0%)	13.7% (12.6%; 14.8%)	11.9% (10.9%; 13.0%)	7.7% (6.4%; 9.2%)
	I	181	86.2% (81.1%; 91.7%)	67.2% (60.3%; 74.8%)	53.3% (46.0%; 61.8%)	44.3% (36.7%; 53.4%)	37.3% (29.5%; 47.1%)	18.5% (9.5%; 36.0%)
	II	167	77.8% (71.5%; 84.6%)	60.0% (52.8%; 68.3%)	53.1% (45.6%; 61.9%)	43.8% (36.0%; 53.3%)	40.9% (32.9%; 50.9%)	15.2% (6.8%; 33.7%)
	III	1,148	64.5% (61.7%; 67.4%)	39.7% (36.9%; 42.8%)	29.9% (27.2%; 32.9%)	24.5% (21.8%; 27.4%)	21.8% (19.2%; 24.8%)	14.2% (11.2%; 18.1%)
	IV	2,944	30.3% (28.6%; 32.0%)	12.3% (11.2%; 13.6%)	7.8% (6.8%; 8.9%)	6.1% (5.2%; 7.1%)	5.0% (4.1%; 6.0%)	3.9% (2.8%; 5.3%)
	X/NA	216	31.9% (26.3%; 38.8%)	17.6% (13.1%; 23.5%)	11.8% (8.1%; 17.1%)	10.5% (7.0%; 15.6%)	9.0% (5.8%; 14.0%)	7.5% (4.4%; 12.9%)
NSCLC	**All**	23,362	64.5% (63.9%; 65.1%)	51.8% (51.2%; 52.5%)	44.7% (44.0%; 45.4%)	40.0% (39.3%; 40.8%)	36.5% (35.8%; 37.3%)	25.4% (23.9%; 26.9%)
	I	5,490	95.5% (94.8%; 96.1%)	89.8% (88.9%; 90.8%)	85.0% (83.8%; 86.1%)	80.9% (79.6%; 82.3%)	76.8% (75.2%; 78.4%)	58.6% (53.8%; 63.9%)
	II	1,849	87.0% (85.4%; 88.7%)	76.3% (74.2%; 78.4%)	69.6% (67.3%; 72.0%)	62.8% (60.2%; 65.5%)	56.6% (53.8%; 59.6%)	41.8% (37.0%; 47.2%)
	III	4,238	71.0% (69.6%; 72.4%)	54.2% (52.7%; 55.8%)	44.9% (43.3%; 46.5%)	39.2% (37.6%; 40.9%)	35.2% (33.5%; 36.9%)	21.6% (19.2%; 24.2%)
	IV	11,157	44.8% (43.9%; 45.8%)	29.9% (29.1%; 30.8%)	22.5% (21.7%; 23.3%)	18.1% (17.3%; 18.9%)	15.4% (14.7%; 16.3%)	8.8% (7.8%; 10.0%)
	X/NA	819	45.3% (42.0%; 48.9%)	32.1% (28.9%; 35.6%)	26.4% (23.3%; 29.8%)	23.1% (20.1%; 26.5%)	21.0% (18.1%; 24.5%)	13.0% (9.8%; 17.3%)
SCC	**All**	4,539	62.7% (61.2%; 64.1%)	47.2% (45.7%; 48.8%)	39.4% (37.9%; 41.0%)	35.2% (33.7%; 36.8%)	31.5% (29.9%; 33.1%)	18.2% (16.0%; 20.6%)

Type	Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	I	1,111	91.8% (90.0%; 93.6%)	81.5% (79.0%; 84.1%)	73.1% (70.1%; 76.2%)	67.1% (63.8%; 70.6%)	61.1% (57.4%; 65.0%)	36.5% (30.6%; 43.6%)
	II	540	80.9% (77.5%; 84.5%)	65.9% (61.8%; 70.3%)	59.1% (54.7%; 63.9%)	53.0% (48.4%; 58.2%)	46.4% (41.5%; 52.0%)	29.8% (22.4%; 39.7%)
	III	1,300	59.9% (57.3%; 62.7%)	40.3% (37.6%; 43.1%)	30.5% (27.9%; 33.3%)	27.4% (24.8%; 30.2%)	24.4% (21.8%; 27.2%)	12.0% (8.8%; 16.3%)
	IV	1,406	36.8% (34.3%; 39.4%)	21.2% (19.1%; 23.5%)	15.4% (13.6%; 17.6%)	12.4% (10.6%; 14.4%)	10.4% (8.7%; 12.4%)	4.7% (2.8%; 8.0%)
	X/NA	182	50.1% (43.2%; 58.0%)	34.2% (27.8%; 42.2%)	26.2% (20.2%; 34.1%)	22.2% (16.4%; 30.1%)	20.8% (15.1%; 28.6%)	14.7% (8.9%; 24.1%)
ADC	**All**	17,607	66.7% (66.0%; 67.4%)	54.7% (53.9%; 55.4%)	47.5% (46.7%; 48.3%)	42.5% (41.7%; 43.4%)	38.9% (38.0%; 39.8%)	28.2% (26.3%; 30.1%)
	I	4,257	96.8% (96.1%; 97.4%)	92.6% (91.6%; 93.5%)	88.6% (87.4%; 89.8%)	85.0% (83.6%; 86.5%)	81.4% (79.7%; 83.1%)	64.8% (58.7%; 71.4%)
	II	1,225	90.3% (88.5%; 92.1%)	81.9% (79.5%; 84.3%)	75.4% (72.7%; 78.2%)	68.3% (65.2%; 71.6%)	61.9% (58.5%; 65.5%)	48.6% (43.4%; 54.4%)
	III	2,654	77.5% (75.8%; 79.1%)	62.2% (60.3%; 64.2%)	52.8% (50.7%; 54.9%)	45.4% (43.3%; 47.7%)	40.7% (38.5%; 43.0%)	26.8% (23.7%; 30.3%)
	IV	9,027	47.7% (46.6%; 48.7%)	32.5% (31.5%; 33.5%)	24.4% (23.5%; 25.4%)	19.6% (18.7%; 20.6%)	16.7% (15.8%; 17.6%)	9.6% (8.4%; 11.0%)
	X/NA	547	46.3% (42.3%; 50.8%)	33.4% (29.5%; 37.8%)	28.3% (24.5%; 32.6%)	25.3% (21.5%; 29.6%)	22.9% (19.1%; 27.3%)	13.8% (9.8%; 19.6%)
LCC	**All**	515	45.1% (40.9%; 49.6%)	32.0% (28.2%; 36.4%)	27.6% (23.9%; 32.0%)	24.6% (20.9%; 28.9%)	22.8% (19.1%; 27.3%)	14.9% (10.2%; 21.5%)
	I	80	86.2% (78.5%; 94.5%)	75.1% (65.6%; 86.0%)	70.6% (60.4%; 82.5%)	63.4% (52.5%; 76.7%)	58.1% (46.7%; 72.4%)	45.5% (27.1%; 76.2%)
	II	40	N<50	N<50	N<50	N<50	N<50	N<50
	III	85	64.1% (54.6%; 75.2%)	47.8% (38.1%; 59.8%)	39.2% (29.8%; 51.5%)	36.4% (27.1%; 48.9%)	33.0% (23.7%; 46.0%)	20.1% (10.9%; 37.1%)
	IV	293	25.2% (20.7%; 30.8%)	12.3% (9.0%; 16.8%)	10.0% (7.0%; 14.3%)	8.1% (5.3%; 12.3%)	8.2% (5.4%; 12.5%)	FU<10y
	X/NA	17	N<50	N<50	N<50	N<50	N<50	N<50
Other NSCLC	**All**	864	44.1% (40.9%; 47.6%)	32.2% (29.2%; 35.6%)	27.8% (24.8%; 31.2%)	25.4% (22.4%; 28.9%)	23.3% (20.2%; 26.9%)	14.8% (10.0%; 21.8%)
	I	104	89.2% (83.0%; 95.9%)	77.7% (69.3%; 87.0%)	72.5% (63.3%; 83.0%)	66.2% (56.1%; 78.2%)	59.2% (48.0%; 73.1%)	42.0% (27.7%; 63.8%)
	II	47	N<50	N<50	N<50	N<50	N<50	N<50
	III	204	59.2% (52.6%; 66.5%)	41.3% (34.8%; 49.0%)	35.4% (28.9%; 43.3%)	34.4% (27.8%; 42.6%)	31.9% (25.0%; 40.6%)	15.4% (7.5%; 31.9%)
	IV	436	24.9% (21.1%; 29.3%)	16.4% (13.2%; 20.3%)	12.9% (10.0%; 16.7%)	12.0% (9.2%; 15.8%)	10.7% (7.9%; 14.4%)	7.7% (4.5%; 13.4%)
	X/NA	73	30.6% (21.6%; 43.2%)	18.3% (11.3%; 29.7%)	13.0% (7.2%; 23.4%)	8.4% (3.9%; 18.0%)	8.4% (3.9%; 18.0%)	8.6% (4.0%; 18.3%)
Other	**All**	4,490	66.2% (64.7%; 67.6%)	57.8% (56.3%; 59.4%)	52.0% (50.4%; 53.7%)	47.6% (45.8%; 49.4%)	45.2% (43.3%; 47.2%)	36.4% (32.9%; 40.2%)

Net Survival Probability, 2015-2024								
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	I	2,308	90.4% (89.0%; 91.8%)	82.4% (80.6%; 84.3%)	75.7% (73.5%; 77.9%)	69.2% (66.7%; 71.8%)	65.7% (62.8%; 68.7%)	52.8% (47.4%; 58.9%)
	II	319	78.6% (73.8%; 83.7%)	66.2% (60.5%; 72.4%)	55.7% (49.4%; 62.8%)	51.3% (44.5%; 59.1%)	52.9% (45.8%; 61.2%)	32.3% (18.7%; 56.0%)
	III	439	44.7% (40.0%; 49.8%)	31.6% (27.2%; 36.6%)	24.3% (20.1%; 29.3%)	22.7% (18.5%; 27.9%)	19.3% (15.1%; 24.6%)	11.7% (7.4%; 18.6%)
	IV	1,130	21.7% (19.3%; 24.3%)	15.6% (13.5%; 18.0%)	13.3% (11.3%; 15.7%)	12.3% (10.2%; 14.8%)	11.4% (9.3%; 13.9%)	9.6% (6.8%; 13.5%)
	X/NA	300	65.6% (60.2%; 71.5%)	56.8% (50.9%; 63.3%)	52.6% (46.5%; 59.5%)	46.8% (40.0%; 54.8%)	44.9% (37.8%; 53.4%)	44.4% (31.8%; 62.0%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation. Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Lung cancer survival trends: by tumour stage

5.1.1. Lung cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	All	32,499	43.3% (42.8%; 43.9%)	19.9% (19.5%; 20.4%)	14.8% (14.3%; 15.2%)	10,531	49.8% (48.8%; 50.8%)	26.7% (25.8%; 27.5%)	20.9% (20.0%; 21.7%)
	I	4,534	82.4% (81.1%; 83.6%)	61.7% (60.0%; 63.3%)	50.8% (49.0%; 52.6%)	1,529	90.2% (88.6%; 91.9%)	75.7% (73.3%; 78.2%)	65.5% (62.8%; 68.3%)
	II	1,943	69.2% (67.1%; 71.4%)	41.9% (39.6%; 44.4%)	32.5% (30.2%; 35.0%)	499	75.1% (71.3%; 79.2%)	49.8% (45.4%; 54.6%)	42.1% (37.5%; 47.1%)
	III	6,402	52.1% (50.8%; 53.3%)	18.8% (17.8%; 19.9%)	11.9% (11.0%; 12.8%)	1,835	59.7% (57.5%; 62.1%)	27.2% (25.2%; 29.4%)	20.3% (18.4%; 22.3%)
	IV	10,644	25.7% (24.8%; 26.5%)	4.7% (4.2%; 5.1%)	2.3% (2.0%; 2.6%)	3,681	32.9% (31.4%; 34.4%)	9.1% (8.2%; 10.1%)	5.3% (4.6%; 6.1%)
	X/NA	9,046	32.9% (31.9%; 33.9%)	13.1% (12.4%; 13.9%)	9.7% (9.0%; 10.4%)	3,013	39.9% (38.1%; 41.7%)	19.0% (17.6%; 20.5%)	13.9% (12.7%; 15.3%)
2010-2014	All	28,418	44.9% (44.3%; 45.5%)	21.8% (21.3%; 22.3%)	16.2% (15.7%; 16.7%)	12,048	52.7% (51.8%; 53.6%)	30.0% (29.1%; 30.9%)	24.2% (23.4%; 25.1%)
	I	4,377	85.1% (83.9%; 86.3%)	63.5% (61.9%; 65.2%)	52.0% (50.2%; 53.8%)	2,157	92.6% (91.3%; 93.8%)	78.1% (76.1%; 80.1%)	69.4% (67.1%; 71.8%)
	II	2,360	71.0% (69.1%; 73.0%)	45.4% (43.3%; 47.7%)	35.2% (33.1%; 37.6%)	796	77.0% (74.0%; 80.1%)	56.3% (52.7%; 60.1%)	47.7% (44.0%; 51.8%)
	III	5,975	54.8% (53.5%; 56.2%)	21.9% (20.9%; 23.1%)	14.4% (13.5%; 15.5%)	2,230	60.2% (58.1%; 62.3%)	30.2% (28.3%; 32.3%)	21.8% (20.1%; 23.7%)
	IV	11,678	24.3% (23.5%; 25.1%)	4.6% (4.2%; 5.1%)	2.5% (2.2%; 2.8%)	5,126	33.9% (32.6%; 35.2%)	9.2% (8.4%; 10.0%)	5.7% (5.1%; 6.4%)
	X/NA	4,143	31.0% (29.6%; 32.5%)	12.0% (10.9%; 13.1%)	8.3% (7.4%; 9.4%)	1,778	38.4% (36.2%; 40.8%)	19.5% (17.6%; 21.5%)	15.2% (13.5%; 17.1%)
2015-2019	All	27,970	50.9% (50.3%; 51.5%)	29.6% (29.0%; 30.2%)	22.7% (22.1%; 23.2%)	14,540	58.2% (57.3%; 59.0%)	37.7% (36.9%; 38.5%)	30.7% (29.9%; 31.6%)
	I	5,067	90.3% (89.3%; 91.2%)	71.8% (70.3%; 73.3%)	59.8% (58.0%; 61.5%)	3,123	93.3% (92.3%; 94.3%)	80.5% (78.9%; 82.2%)	71.9% (70.0%; 73.9%)
	II	2,263	79.4% (77.6%; 81.2%)	54.1% (51.8%; 56.5%)	43.3% (40.9%; 45.9%)	1,025	81.9% (79.4%; 84.4%)	61.7% (58.5%; 65.0%)	49.7% (46.4%; 53.2%)

Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability		
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	5,915	59.4% (58.1%; 60.7%)	30.0% (28.8%; 31.3%)	21.9% (20.7%; 23.1%)	2,763	65.1% (63.3%; 67.0%)	36.8% (35.0%; 38.7%)	28.6% (26.8%; 30.4%)
	IV	13,007	29.2% (28.5%; 30.0%)	10.6% (10.1%; 11.2%)	6.6% (6.2%; 7.1%)	6,813	37.4% (36.2%; 38.5%)	16.2% (15.3%; 17.1%)	10.9% (10.1%; 11.7%)
	X/NA	1,859	34.0% (31.8%; 36.3%)	17.4% (15.6%; 19.4%)	11.2% (9.7%; 13.1%)	892	45.9% (42.7%; 49.4%)	27.5% (24.6%; 30.8%)	23.2% (20.3%; 26.6%)
2020-2024	**All**	27,981	56.4% (55.8%; 57.0%)	35.8% (35.1%; 36.4%)	27.7% (26.9%; 28.5%)	17,903	64.5% (63.7%; 65.2%)	45.3% (44.5%; 46.1%)	37.3% (36.3%; 38.3%)
	I	6,306	90.7% (89.9%; 91.6%)	74.0% (72.5%; 75.4%)	59.9% (57.7%; 62.1%)	4,848	94.1% (93.4%; 94.9%)	82.6% (81.3%; 84.0%)	73.5% (71.3%; 75.8%)
	II	2,221	81.7% (79.9%; 83.5%)	58.9% (56.4%; 61.4%)	48.3% (45.1%; 51.6%)	1,308	87.8% (85.9%; 89.8%)	70.4% (67.5%; 73.5%)	60.3% (56.4%; 64.5%)
	III	5,372	64.9% (63.6%; 66.2%)	37.1% (35.6%; 38.6%)	27.8% (26.1%; 29.6%)	3,059	70.0% (68.3%; 71.7%)	43.7% (41.8%; 45.7%)	33.8% (31.6%; 36.2%)
	IV	13,595	34.1% (33.2%; 34.9%)	14.6% (13.9%; 15.2%)	10.1% (9.4%; 10.8%)	8,413	42.7% (41.6%; 43.8%)	21.3% (20.4%; 22.3%)	15.4% (14.4%; 16.5%)
	X/NA	719	41.4% (37.9%; 45.4%)	25.8% (22.4%; 29.6%)	17.8% (14.1%; 22.6%)	443	51.3% (46.7%; 56.3%)	35.0% (30.5%; 40.3%)	25.9% (20.8%; 32.2%)

6.1. Lung cancer mortality: by region

6.1.1. Lung cancer mortality by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	0	1	5	7	22	32	78	178	382	557	631	658	482	340	115	31	3,519	66.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[1.3]	[1.9]	[5.7]	[8.6]	[19.7]	[44.2]	[101.9]	[175.1]	[236.9]	[323.7]	[386.0]	[426.5]	[367.0]	[511.6]	[61.1]	(63.8; 68.2)
Brussels	0	0	0	0	0	0	1	1	1	2	6	16	35	35	27	44	22	19	8	4	221	59.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[2.1]	[2.2]	[4.5]	[14.6]	[45.2]	[121.4]	[163.9]	[160.5]	[348.5]	[273.5]	[379.8]	[347.4]	[746.3]	[36.3]	(51.7; 67.8)
Flanders	0	0	0	0	0	1	0	4	14	17	34	89	198	317	382	401	316	227	72	18	2,090	62.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[1.9]	[6.3]	[8.1]	[14.8]	[36.7]	[86.5]	[161.8]	[232.7]	[307.6]	[383.3]	[421.9]	[346.1]	[453.4]	[62.3]	(59.5; 64.9)
Wallonia	0	0	0	0	0	0	4	2	7	13	38	73	149	205	222	213	144	94	35	9	1,208	75.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.3]	[1.7]	[6.0]	[11.0]	[30.3]	[58.5]	[127.4]	[203.3]	[260.0]	[353.2]	[418.7]	[449.2]	[425.5]	[579.2]	[67.1]	(70.9; 79.5)
Females																						
Belgium	0	0	0	1	0	1	2	3	10	30	61	143	239	364	437	349	238	163	76	24	2,141	33.4
	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.3]	[0.5]	[0.8]	[2.6]	[8.2]	[15.7]	[36.0]	[62.6]	[107.5]	[147.1]	[142.0]	[136.6]	[121.8]	[107.2]	[115.3]	[36.1]	(31.9; 34.8)
Brussels	0	0	0	0	0	0	0	0	1	1	4	9	11	19	26	18	22	9	6	5	131	26.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[2.4]	[10.5]	[26.4]	[36.4]	[76.0]	[121.2]	[100.0]	[171.3]	[91.8]	[105.8]	[240.2]	[20.7]	(21.6; 30.7)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	1	0	1	2	2	4	12	26	78	138	198	232	202	139	94	43	8	1,180	30.4
	[0.0]	[0.0]	[0.0]	[0.6]	[0.0]	[0.5]	[0.9]	[0.9]	[1.8]	[5.8]	[11.6]	[33.0]	[60.4]	[97.9]	[132.1]	[134.4]	[127.0]	[110.1]	[97.7]	[65.3]	[34.5]	(28.7; 32.2)
Wallonia	0	0	0	0	0	0	0	1	5	17	31	56	90	147	179	129	77	60	27	11	830	40.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[4.2]	[14.3]	[24.7]	[44.3]	[73.2]	[131.9]	[178.9]	[166.6]	[148.3]	[155.2]	[127.4]	[169.6]	[44.1]	(37.8; 43.4)

7.1. Lung cancer mortality trends: by region

7.1.1. Lung cancer mortality trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	4,815	5,018	4,982	4,884	4,992	4,888	4,960	4,868	4,576	4,592	4,601	4,332	4,359	3,969	3,950	3,841	3,675	3,800	3,655	3,519		
	CR	94.6	98.2	96.9	94.3	95.6	92.8	93.4	90.6	84.5	84.3	84.0	78.7	78.7	71.3	70.6	68.2	64.9	66.9	64.0	61.1		
	ESR2013	125.2	129.3	124.8	120.1	120.6	115.6	115.4	111.6	102.7	101.2	99.7	92.3	91.8	81.5	80.6	77.1	72.4	74.0	69.5	66.0	-3.5 (-3.7; -3.2)	2004-2023
																						-1.8 (-2.6; -1.0)	2004-2010
																						-4.2 (-5.2; -3.2)	2011-2014
																						-4.2 (-4.7; -3.7)	2015-2023
Brussels	**N**	348	364	354	306	344	325	373	324	301	313	306	281	286	280	237	267	249	250	215	221		
	CR	72.4	75.3	72.3	61.6	68.1	63.0	70.8	59.7	54.4	55.7	54.0	49.1	49.3	48.1	40.4	45.1	41.7	41.7	35.8	36.3		
	ESR2013	108.6	115.6	109.0	94.3	105.5	96.1	113.5	96.5	88.5	90.0	88.1	80.7	81.7	79.5	67.4	73.5	68.7	68.8	57.3	59.8	-3.3 (-3.9; -2.8)	2004-2023
Flanders	**N**	2,830	2,997	2,970	2,981	2,997	2,917	2,948	2,955	2,714	2,724	2,750	2,559	2,598	2,264	2,339	2,274	2,184	2,230	2,183	2,090		
	CR	95.4	100.6	99.1	98.8	98.6	95.2	95.5	94.9	86.6	86.4	86.9	80.4	81.2	70.3	72.2	69.8	66.6	67.7	65.8	62.3		
	ESR2013	122.6	127.1	122.5	120.0	118.8	113.2	111.5	109.7	98.8	97.2	96.4	87.7	87.7	74.4	76.3	73.1	68.6	69.1	66.0	62.2	-3.7 (-4.0; -3.4)	2004-2023
																						-1.9 (-3.0; -0.8)	2004-2010
																						-4.9 (-6.2; -3.5)	2011-2014
																						-4.4 (-5.0; -3.7)	2015-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Wallonia	**N**	1,637	1,657	1,658	1,597	1,651	1,646	1,639	1,589	1,561	1,555	1,545	1,492	1,475	1,425	1,374	1,300	1,242	1,320	1,257	1,208		
	CR	99.8	100.6	100.1	95.8	98.4	97.5	96.4	92.7	90.5	89.7	88.7	85.3	84.0	80.8	77.6	73.2	69.7	74.0	70.1	67.1		
	ESR2013	134.4	137.6	133.5	127.1	128.2	125.2	123.2	118.9	114.1	111.3	108.6	104.0	102.2	96.5	92.0	86.0	80.4	85.7	79.0	75.2	-3.2 (-3.3; -3.0)	2004-2023
																						-2.2 (-2.7; -1.8)	2004-2013
																						-4.0 (-4.4; -3.6)	2014-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Lung cancer mortality trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	1,268	1,365	1,441	1,477	1,550	1,551	1,753	1,842	1,730	1,884	1,922	1,936	1,936	1,833	1,921	2,008	1,994	1,918	2,134	2,141		
	CR	23.9	25.6	26.8	27.3	28.5	28.3	31.7	33.0	30.8	33.3	33.9	33.9	33.8	31.9	33.2	34.6	34.2	32.8	36.3	36.1		
	ESR2013	24.5	26.1	27.2	27.5	28.8	28.3	31.6	32.8	30.5	33.1	33.3	33.2	32.7	30.7	31.6	32.9	32.1	30.8	33.8	33.4	1.4 (1.1; 1.8)	2004-2023
																						3.7 (2.7; 4.8)	2004-2011
																						0.2 (-1.3; 1.8)	2012-2015
																						0.1 (-0.8; 0.9)	2016-2023
Brussels	**N**	181	159	172	170	159	170	158	180	165	182	169	176	182	165	145	178	153	139	155	131		
	CR	34.8	30.4	32.5	31.8	29.3	30.8	28.1	31.2	28.2	30.7	28.3	29.2	29.9	27.1	23.7	28.9	24.7	22.4	24.9	20.7		
	ESR2013	38.5	33.6	36.8	35.2	33.6	35.6	32.3	37.2	33.7	37.8	34.9	36.7	36.6	33.9	28.9	35.2	30.4	28.9	31.9	26.2	-1.3 (-1.8; -0.7)	2004-2023
																						0.0 (-1.0; 0.9)	2004-2016
																						-3.3 (-5.0; -1.6)	2017-2023
Flanders	**N**	613	711	772	775	817	792	923	1,002	888	991	1,016	1,031	1,047	978	1,016	1,118	1,137	1,060	1,192	1,180		
	CR	20.1	23.2	25.1	25.0	26.2	25.2	29.1	31.4	27.6	30.7	31.3	31.6	32.0	29.7	30.7	33.6	34.0	31.6	35.2	34.5		
	ESR2013	20.2	23.4	24.8	24.5	25.6	24.6	28.2	30.1	26.6	29.2	29.4	29.7	29.7	27.3	27.9	30.5	30.5	28.3	31.2	30.4	1.7 (1.2; 2.1)	2004-2023
																						3.5 (2.3; 4.7)	2004-2012
																						0.4 (-0.4; 1.2)	2013-2023
Wallonia	**N**	474	495	497	532	574	589	672	660	677	711	737	729	707	690	760	712	704	719	787	830		
	CR	27.2	28.3	28.3	30.1	32.3	33.0	37.4	36.4	37.2	38.9	40.2	39.6	38.3	37.3	41.0	38.3	37.8	38.6	42.1	44.1		
	ESR2013	28.5	28.9	28.9	30.7	33.3	33.4	37.5	36.8	36.9	39.1	39.9	38.8	37.1	36.1	39.1	36.7	35.6	36.2	39.2	40.6	1.7 (1.3; 2.1)	2004-2023
																						4.5 (3.2; 5.9)	2004-2011
																						0.1 (-1.8; 2.1)	2012-2015
																						0.1 (-1.0; 1.1)	2016-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026